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ARTICLE
The Missing Link: U.S. Regulation of
Consumer Cosmetic Products to Protect
Human Health and the Environment
VALERIE J. WATNICK*

In August 2012, a well-known baby shampoo company
announced its intention to remove multiple toxic substances from
nearly all of its products by 2015.1 The announcement came on
the heels of its earlier promise to remove these chemicals from
just its baby products by 2013.2
While the long timeframe of this planned corporate action—
three years—is shocking, it is even more worrisome that these

* Professor Valerie J. Watnick is Chair and Professor of the Department of
Law at Baruch College, Zicklin School of Business, City University of New York.
She teaches environmental law and business law at Baruch, and has published
multiple articles on toxics regulation, risk assessment, and the regulation of
pesticides. An earlier version of this research was presented at the Hawaii
International Conference on Business Law in May 2013 in Honolulu, Hawaii.
Prof. Watnick is a graduate of Cornell Law School, class of 1988, and Bucknell
University, class of 1985.
1. CBS News Staff, Johnson & Johnson to Phase Out Potentially Harmful
Chemicals by 2015, CBSNEWS (Aug. 15, 2012, 2:05 PM), http://www.cbsnews.
com/8301-504763_162-57493890-10391704/johnson-johnson-to-phase-outpotentially-harmful-chemicals-by-2015/. Johnson & Johnson has reportedly
made good on its promise to remove formaldehyde and 1,4-dioxane from its baby
shampoo.
Katie Thomas, The ‘No More Tear’ Shampoo, Now with No
Formaldehyde, N.Y. TIMES (Jan. 17, 2014), http://www.nytimes.com/2014/01/18/
business/johnson-johnson-takes-first-step-in-removal-of-questionable-chemicalsfrom-products.html?_r=0.
2. CBS News Staff, supra note 1; see also Associated Press, Group:
Johnson’s Baby Shampoo a Cancer Risk, CBSNEWS (Nov. 1, 2011, 2:55 AM),
http://www.cbsnews.com/8301-204_162-20128253/group-johnsons-babyshampoo-a-cancer-risk/.
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substances, including formaldehyde, a known carcinogen,3 and
1,4-dioxane, a substance linked to cancer in animal studies and
classified by the U.S. Environmental Protection Agency (EPA) as
a probable human carcinogen,4 were even linked to products
designed for babies in the first instance. To complicate matters
further, not all of these toxic substances are even listed on
product labels. Formaldehyde, for example, is released over time
from the interaction of substances in the shampoo with the toxic
quaternium-15, which, until recently, was present in these
products and found on product labels.5
The other shocking part of this corporate announcement is
that these products are not from some unknown manufacturer
sold at the fringe of U.S. commerce. Rather, they come from a
corporate giant that sells cosmetic products in widespread use
every day—all over the country. The news highlights the popular
consumer misconception that federal cosmetic law is protective of
human health.6 In reality, federal law simply does not prohibit
the creation of carcinogens or the addition of other toxins in
cosmetic products in the United States.7 To put a bleaker face on
3. The EPA lists formaldehyde as a “probable human carcinogen” that has
been shown to cause cancer in animals. Integrated Risk Information System:
Formaldehyde, EPA, http://www.epa.gov/iris/subst/0419.htm (last visited Feb.
19, 2014); An Introduction to Indoor Air Quality, EPA, http://www.epa.
gov/iaq/formaldehyde.html (last visited Feb. 19, 2014). Formaldehyde is also a
skin, eye, and respiratory irritant. CBS News Staff, supra note 1.
4. Technology Transfer Network – Air Toxics Website, 1,4-Dioxane (1,4Diethyleneoxide), EPA, http://www.epa.gov/ttnatw01/hlthef/dioxane.html (last
visited Feb. 19, 2014).
5. CBS News Staff, supra note 1. Another worrisome chemical that causes
the release of formaldehyde in cosmetic products is imidazolidinyl urea. This
man-made chemical has been studied by the National Cancer Institute and was
nominated as early as 2003 for inclusion in the National Toxicology Program.
TECHNICAL RESOURCES INTERNATIONAL, INC., IMIDAZOLIDINYL UREA 1 (2004),
available at http://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/
imidazolidinylurea_508.pdf. When paired with parabens, imidazolidinyl urea is
one of the most widely used cosmetic preservatives in the world. Id. Another
commonly used substance in personal care products is DMDM hydantoin, which
also causes the release of formaldehyde over time. Katie Thomas, Johnson &
Johnson to Remove Formaldehyde from Products, N.Y. TIMES (Aug. 15, 2012),
http://www.nytimes.com/2012/08/16/business/johnson-johnson-to-removeformaldehyde-from-products.html?_r=0.
6. An August 2012 CBS News story contains this shocking statement: “[T]he
U.S. Food and Drug Administration doesn’t regulate cosmetic products.” CBS
News Staff, supra note 1.
7. See id.
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U.S. cosmetics regulation, the company in question had already
removed these hazardous substances from its products for sale in
other regions, such as the United Kingdom and Scandinavia.8
Worse still, consumers in the United States willing to pay more
for their baby shampoo could purchase the company’s “natural”
baby shampoo, a product marketed and sold without a dose of 1,4dioxane.9
Unfortunately, the headline from this baby shampoo giant is
only the tip of the iceberg with regard to the regulation of
consumer cosmetics. For the average U.S. consumer, there is an
enormous “gaping hole”10 or “missing link” in federal law that
allows these questionable product formulations.
The Safe Cosmetics and Personal Care Products Act of 2013
(House Bill 1385) would require the U.S. Food and Drug
Administration (FDA) to finally set rules banning carcinogens
and many toxins from cosmetics in the United States.11 The
Cosmetics Safety Enhancement Act of 2012 (Enhancement Act),12
introduced by Representative Frank Pallone, Jr. (D-NJ), and the
Cosmetic Safety Amendments Act of 2012 (Amendments Act),13
introduced by Representative Leonard Lance (R-NJ) were
likewise attempts to begin to strengthen the regulation of U.S.
cosmetics.

8. Toxic Baby Shampoo: Johnson & Johnson Agrees to Global Reformulation
Under Pressure from Health Groups, THE CAMPAIGN FOR SAFE COSMETICS (Nov.
1, 2011), http://safecosmetics.org/article.php?id=888.
9. CBS News Staff, supra note 1. The cosmetics industry is a $60 billion per
year industry, and it has lobbied against stricter regulation. Jim Avila, FDA
Regulation of Cosmetics Nears Despite Industry Objections, ABCNEWS (Apr. 30,
2012, 9:07 PM), http://abcnews.go.com/blogs/lifestyle/2012/04/fdas-regulationover-cosmetics-nears-despite-industry-backlash.
10. Then-U.S. Representative Edward Markey (now Massachusetts Senator),
the 2011 sponsor of the Safe Cosmetics Act, said the 2011 version of the Act
would close a “gaping hole” in federal law. Associated Press, J&J Steadily
Removing Toxins from Baby Products, THE CAMPAIGN FOR SAFE COSMETICS (Nov.
16, 2011), http://safecosmetics.org/article.php?id=907.
11. See Safe Cosmetics and Personal Care Products Act of 2013, H.R. 1385,
113th Cong. (2013), available at http://www.govtrack.us/congress/bills/113/
hr1385. This bill was introduced in March 2013 and has been referred to
committee. Id.
12. See generally Cosmetics Safety Enhancement Act of 2012, H.R. 4262,
112th Cong. (2012).
13. See generally Cosmetic Safety Amendments Act of 2012, H.R. 4395, 112th
Cong. (2012).
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Neither of these latter bills, however, went far enough to
address the fundamental weaknesses in how we regulate toxic
substances in consumer products and in U.S. commerce generally,
and previous versions of the House Bill 1385 stalled in
committee.
The Act seems unlikely in any forthcoming
Congressional session to garner necessary support.14
This article explores these lax regulatory efforts and their
connection to risk assessment, and proposes changes to our
current toxics regulatory paradigm. Part I of this article explores
our current regulatory approach for consumer cosmetics. Part II
discusses the specific and dire concerns regarding chemicals that
are suspected carcinogens and those suspected of disrupting the
human endocrine system. The article argues in Part III that
because the framework for our current regulation of consumer
cosmetic products is not designed to be protective of human
health, our regulatory paradigm must shift dramatically in the
future if this is to become our true goal. Part IV of the article
compares our federal efforts to regulate toxic substances in
cosmetics with those in other developed countries and at the state
level in the United States. This section concludes that we lag far
behind in our health protective regulatory efforts relative to other
jurisdictions. If we are to make the protection of human health a
fundamental goal of our toxics regulatory system and specifically,
our cosmetic product regulation, we must change our normative
goals and operate from a more precautionary stance. In Part V,
the article reviews past and current federal legislative proposals
regarding cosmetic regulation, and makes suggestions on how the
current proposal could be strengthened to make U.S. cosmetics
safer, and have a greater potential to protect human health.

14. See H.R. 1385; see also infra note 365 and accompanying text.
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REGULATION OF COSMETICS

A. History of the United States’ Regulatory System
a.

The Federal Food and Drugs Act

Although federal regulation of cosmetic products in the
United States did not begin until 1938,15 the course of early
regulatory efforts regarding food, drugs, and other chemicals
influenced the current regulation of cosmetics. Between 1879 and
1906, dozens of Congressional bills seeking to regulate food and
drugs had failed to pass.16 The Pure Food and Drugs Act of 1906,
however, finally authorized the Bureau of Chemistry to prohibit
adulterated or mislabeled food and drugs.17 Adulterated drugs
were those whose strength, quality, or purity departed from
professional standards,18 while misbranded drugs included those
with misleading or false packaging or labeling.19 “The central
purpose of the food and drug legislation was to prohibit
adulteration and misrepresentation. This perfectly laudable
objective amounted to little more than a modest extension of the
common law prohibition against fraudulent conduct.”20
These early efforts to regulate drugs were often hindered by
narrow judicial interpretations and high evidentiary burdens. In
1911, the Supreme Court of the United States, in United States v.
Johnson, held that false statements on a drug’s label indicating it
was effective in curing cancer did not cause the drug to be

15. Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. §§ 301-399f
(2012).
16. FDA History - Part I: The 1906 Food and Drugs Act and its Enforcement,
FDA, http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054819.htm
(last visited Feb. 19, 2014) [hereinafter FDA History].
17. Pure Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768, § 2
(1906); FDA History, supra note 16. In 1927, the relevant operations of the
Bureau of Chemistry were moved to the newly created Food, Drug, and
Insecticide Administration, later known as the FDA. Significant Dates in U.S.
Food and Drug Law History, FDA, http://www.fda.gov/AboutFDA/WhatWeDo/
History/Milestones/ucm128305.htm (last visited Feb. 19, 2014).
18. Pure Food and Drugs Act § 7.
19. Id. § 8.
20. Robert L. Rabin, Federal Regulation in Historical Perspective, 38 STAN. L.
REV. 1189, 1228 (1986).
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mislabeled under the Pure Food and Drugs Act.21 The Court
noted that “the phrase [mislabeled] is aimed not at all possible
false statements, but only at such as determine the identity of the
article, possibly including its strength, quality and purity . . . .”22
Congress amended the Act in the following year to do an end run
around Johnson, by specifically prohibiting false therapeutic
claims for drugs.23
While the amended Pure Food and Drugs Act provided some
minimum regulation of drugs, it still had significant
shortcomings.24 The Amendment attempted to protect consumers
by allowing prosecution for false therapeutic statements,
however, the Amendment also required proof that such
statements were intended to defraud consumers, and thus
significantly increased the government’s burden to win cases.25
Additionally, the Act did not require that drugs be proven
safe or effective prior to distribution.26 As a result, a number of

21. United States v. Johnson, 221 U.S. 488, 498 (1911).
22. Id. at 497. The Johnson holding that, despite labeling indicating that a
drug was effective in curing cancer (when it was not so proven), the drug was
not “misbranded,” appeared to directly conflict with the clear language of the
Pure Food and Drug Act: “[T]he term ‘misbranded’ . . . shall apply to all drugs, . .
. the package or label of which shall bear any statement, design, or device
regarding such article, or the ingredients or substances contained therein which
shall be false or misleading in any particular . . . .” Id. (citing Pure Food and
Drugs Act § 8).
23. Sherley Amendment of 1912, 37 Stat. 416 (1912). (A drug shall be
misbranded “[i]f its package or label shall bear or contain any statement, design,
or device regarding the curative or therapeutic effect of such article or any of the
ingredients or substances contained therein, which is false and fraudulent.”).
24. See supra notes 17-20 and accompanying text.
25. Marc T. Law, How do Regulators Regulate? Enforcement of the Pure Food
and Drugs Act, 1907-38, 22(2) J.L. ECON. & ORG. 459, 472-73 (2006). The
Supreme Court of the United States, in a case construing the meaning of the
Sherley Amendment of 1912, held that: “it must be found that the statement
contained in the package was put there to accompany the goods with actual
intent to deceive,—an intent which may be derived from the facts and
circumstances, but which must be established.” Seven Cases v. United States,
239 U.S. 510, 517 (1916). But see United States v. 47 Bottles, 200 F. Supp. 1, 6
(D.N.J. 1961) (interpreting the corresponding mislabeled drug provision of the
later FDCA and finding that “no fraudulent intent . . . need be shown . . .”).
26. See Johnson, 221 U.S. at 496; see also FDA History, supra note 16 (“The
basis of the [Pure Food and Drugs Act] rested on the regulation of product
labeling rather than pre-market approval.”).
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harmful products continued to be sold and consumed.27 The most
shocking case involved Elixir Sulfanilamide.28 Sulfanilamide
drugs were used throughout the 1930s without incident, until one
manufacturer produced a liquid form of the drug dissolved in a
type of antifreeze.29 Over 100 people died after using the drug,
and the public pressured Congress to pass the Federal Food,
Drug, and Cosmetic Act (FDCA) of 1938, which forms the basis of
all cosmetics regulation in the United States today.30
b.

The FDCA

The FDCA of 193831 was intended to address many of the
problems with the Pure Food and Drugs Act.32
Congress
specifically included cosmetics within the new FDCA, partly in
response to the FDA’s publicizing of many defective and harmful
cosmetic products prior to the bill’s passage.33 The FDCA
explicitly banned misbranded or adulterated cosmetics.34
Adulterated cosmetics under the Act include:
[1] [Cosmetics] that [bear] or [contain] any poisonous or
deleterious substance which may render it injurious to users

27. See Patricia I. Carter, Federal Regulation of Pharmaceuticals in the
United States and Canada, 21 LOY. L.A. INT’L & COMP. L.J. 215, 217-18 (1999).
28. See id. at 218.
29. Id.
30. Id.
31. See 21 U.S.C. §§ 301-399f.
32. See David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its
Legislative History and Its Substantive Provisions, 6 LAW & CONTEMP. PROBS. 2,
12-13 (1939).
33. See FDA History Part II: The 1938 Food, Drug, and Cosmetic Act, FDA,
http://www.fda.gov/aboutFDA/WhatWeDo/History/origin/ucm054826.htm (last
visited Feb. 19, 2014) (“The FDA . . . [assembled] a collection of products that
illustrated shortcomings in the [Pure Food and Drug Act]. It included . . . LashLure, an eyelash dye in which a number of women suffered injuries to their
eyes, including one confirmed case of permanent blindness . . . .”).
34. 21 U.S.C. § 331(a). “Cosmetic” is defined as:
(1) articles intended to be rubbed, poured, sprinkled, or sprayed on,
introduced into, or otherwise applied to the human body or any part
thereof for cleansing, beautifying, promoting attractiveness, or
altering the appearance, and (2) articles intended for use as a
component of any such articles; except that such term shall not
include soap.
Id. § 321(i).
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under the conditions of use prescribed in the labeling thereof, or
under such conditions of use as are customary or usual; . . . [2]
[cosmetics consisting] in whole or in part of any filthy, putrid, or
decomposed substance; . . . [3] [cosmetics made or held] under
insanitary conditions whereby [they] may have become
contaminated with filth, or whereby [they] may have been
rendered injurious to health, . . . [4] [and cosmetics with a]
container composed, in whole or in part, of any poisonous or
deleterious substance which may render the contents injurious to
health . . . .35

A cosmetic product can also be “misbranded” under the FDCA if:
(1) its labeling is false or misleading; (2) its label does not contain
the name and address of the manufacturer, packer, or distributor,
or an accurate ingredient list; or (3) if “any word, statement, or
other information required by . . . this [Act] to appear on the label
. . . is not prominently placed thereon . . . in such terms as to
render it likely to be read and understood by the ordinary
individual under customary conditions of purchase and use.”36
These
statutory
definitions
of
“misbranded”
and
“adulterated” remain in place today, although originally enacted
in 1938,37 and even as we have made vast strides in our scientific
and technological knowledge in the last century.38 The statutory
nomenclature speaks of “putrid” and “filthy” products made under
unsanitary conditions, evincing a lack of understanding of
current corporate production, and a total lack of concern about
the long-term effects of a cosmetic product on the user.39 Instead,
the FDCA was then and continues today to be mainly concerned
with the immediate and short-term effects of a consumer product
and its ingredients. By these standards, most cosmetic products
are considered safe in the United States today, absent some
meaningful proof of harm in the long-term, which is not regularly
available.40
35.
36.
37.
38.

Id. § 361(a)-(d).
Id. § 362(a)-(c).
21 U.S.C. §§ 361, 362.
WHO WILL KEEP THE PUBLIC HEALTHY? EDUCATING PUBLIC HEALTH
PROFESSIONALS FOR THE 21ST CENTURY 27 (Kristine Gebbie et al. eds., 2003),
available at http://www.nap.edu/openbook.php?isbn= 030908542X.
39. See 21 U.S.C. § 361(b)-(c).
40. See Mary O’Brien, Our Current Toxics Use Framework, Our Stolen
Future, and Our Options, 11 J. ENVTL. L. & LITIG. 331, 346-51 (1996) (reviewing
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Recent Changes to the FDCA

While the FDCA remains largely similar to the original
statute, several recent changes deserve note. Under the FDCA,
labeling requirements include specific warning labels for coal-tar
hair dye,41 in addition to the general prohibitions on false or
misleading labels or packaging, exclusive of ingredient lists.42
The Fair Packaging and Labeling Act43 also contains provisions
requiring product labels to conspicuously include information
about the manufacturer, packer or distributor, and net quantity
information.44 The Special Packaging of Household Substances
for Protection of Children Act, commonly known as the Poison
Prevention Packaging Act of 1970,45 allows the Consumer
Product Safety Commission to set special packaging guidelines
for consumer products that may have a high degree of risk to
children.46 Specific labeling and packaging requirements also
attach under FDA regulations within the existing legal
framework.47
An amendment to the FDCA in 1997 also
outlawed—with
minor
exceptions—any
state
or
local
requirements for labeling or packaging of cosmetics that are
different from requirements under the Act, the Poison Prevention
Packaging Act of 1970, or the Fair Packaging and Labeling Act.48
In July 2012, as part of an effort to extend current FDA userfee programs and to institute new fees, Congress also added a
section on “nanotechnology” to the FDCA.49 “Nanotechnology,”
“nanomaterials,” and “nanoparticles” all refer to new materials
THEO COLBORN ET AL., OUR STOLEN FUTURE: ARE WE THREATENING OUR
FERTILITY, INTELLIGENCE, AND SURVIVAL?—A SCIENTIFIC DETECTIVE STORY
(1996)).
41. 21 U.S.C. § 361(a).
42. Id. § 362(a).
43. Fair Packaging and Labeling Program, 15 U.S.C. §§ 1451-1461 (2012).
44. Id. § 1453(a)(1)-(2).
45. Special Packaging of Household Substances for Protection of Children, 15
U.S.C. §§ 1471-1477 (2012).
46. See id. § 1472(a)(1).
47. See generally 21 C.F.R. §§ 701.1-701.30 (2014) (FDA regulations for
cosmetic labeling); 16 C.F.R. §§ 500.1-500.29 (2014) (Federal Trade Commission
regulations under section 4 of the Fair Packaging and Labeling Act); 16 C.F.R.
§§ 1700.1-1700.20 (2014) (Consumer Product Safety Commission regulations
under the Poison Prevention Packaging Act of 1970).
48. 21 U.S.C. § 379s(a).
49. See id. § 399e.
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created from the manipulation of atoms and molecules at the
“nanometer scale,” that is, from 1 nanometer to 100
nanometers.50 The use of such nanoparticles in cosmetic products
in recent years has increased dramatically, often because these
new materials have new or enhanced properties, including “color,
transparency, solubility[,] and chemical reactivity . . . .”51 Certain
nanoparticles, however, have been found to have high risks of
health concerns, often because the very small size of the particles
increases the likelihood of inhalation or migration beyond the
surface of the skin.52 Furthermore, their small size is believed to
increase the possibility that they might interact with more
sensitive cells of the body,53 such as in the digestive tract or
respiratory system.
This new section in the FDCA attempts to address these
concerns by authorizing the FDA to “intensify and expand
activities related to enhancing scientific knowledge regarding
nanomaterials” intended for use in products regulated by the
FDA, and to collect user fees to further this purpose.54 The
section notes that these new studies will address issues including
“the potential toxicology of such nanomaterials, the potential
benefit of new therapies derived from nanotechnology, the effects
of such nanomaterials on biological systems, and the interaction
of such nanomaterials with biological systems.”55
B. Cosmetic Ingredient Review and Industry SelfRegulation
The cosmetics
made a minimal
Ingredient Review
cosmetic industry’s

industry has over the last forty years also
attempt to self-regulate.
The Cosmetic
Panel (CIR) was established in 1976 by the
trade association,56 and is also funded by that

50. Raj Silpa et al., Nanotechnology in Cosmetics: Opportunities and
Challenges, 4 J. PHARMACY & BIOALLIED SCI. 186, 186 (2012) (noting that one
nanometer is one billionth of a meter).
51. Id.
52. Id. at 188.
53. See Silpa et al., supra note 50, at 188.
54. 21 U.S.C. § 399e(a).
55. Id.
56. About the Cosmetic Ingredient Review, COSMETIC INGREDIENT REV.,
http://www.cir-safety.org/about (last visited Feb. 20, 2014) (The CIR was set up
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association.57 The CIR assesses the safety of ingredients used in
cosmetic products.58 Voting panel members include doctors and
scientists, plus three non-voting members representing the
cosmetics industry, consumer groups, and the government.59
The importance of the CIR’s findings to FDA determinations
regarding the safety of cosmetic products is revealed in references
to the expert panel’s evaluations in a number of the FDA’s
rulemaking notices.60 The EPA61 and the Occupational Safety
and Health Administration62 have also referenced CIR studies in
their respective actions. The FDA has nonetheless noted, that
CIR determinations do not serve as the sole source of evidence for
rulemaking actions regarding cosmetics.63
While CIR review is a laudable and ambitious program of
self-regulation, experts have estimated that only between 11%
and 13% of ingredients used in cosmetics have actually been
subject to CIR analysis.64 Additionally, the CIR has only found
and is funded by what was the Cosmetic, Toiletry, and Fragrance Association,
now the Personal Care Products Council, with the support of the FDA and the
Consumer Federation of America.).
57. Id.
58. How Does CIR Work?, COSMETIC INGREDIENT REV., http://www.cir-safety.
org/how-does-cir-work (last visited Feb. 20, 2014).
59. Id.
60. See, e.g., 50 Fed. Reg. 39,854 (Sept. 30, 1985) (notice of proposed
rulemaking regarding dental anti-cavity products); 70 Fed. Reg. 1721, (Jan. 10,
2005) (guidance for industry regarding cosmetic products containing alpha
hydroxy acids); 68 Fed. Reg. 32,232 (May 29, 2003) (notice of proposed
rulemaking regarding anti-plaque and anti-gingivitis products).
61. See, e.g., 54 Fed. Reg. 8116 (Feb. 24, 1989) (notice of intent to cancel
regulations for pesticides containing captan); 60 Fed. Reg. 54,637 (Oct. 25, 1995)
(proposed rule regarding jojoba oil); 76 Fed. Reg. 56,644 (Sept. 14, 2011) (notice
of final rule regarding sulfur dioxide).
62. See, e.g., 52 Fed. Reg. 46,168 (Dec. 4, 1987) (final rule regarding
occupational exposure to formaldehyde).
63. 58 Fed. Reg. 33,700 (June 8, 1993). The FDA noted that
[t]hese [CIR] reviews are used primarily by industry to make selfdeterminations of cosmetic ingredient safety. The agency may, or
may not, comment on any CIR. Even where FDA comments on a
CIR, there would be little likelihood that agency rulemaking would
result. In situations where such a review does serve as a stimulus
for a rulemaking proceeding, the review would not be the sole reason
for the proceeding.
Id.
64. See Rajiv Shah & Kelly E. Taylor, Concealing Danger: How the
Regulation of Cosmetics in the United States Puts Consumers at Risk, 23
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eleven chemicals or groups of chemicals actually unsafe for use in
cosmetics since the panel first came into existence almost forty
years ago.65 Moreover, manufacturers are not even required to
follow CIR’s published determinations.66 In California’s recently
enacted laws regulating cosmetic products,67 the statement of
legislative findings notes that “54 cosmetic products violate the
CIR’s own safe use recommendations to manufacturers by
containing an ingredient that the CIR has found is not safe for
the specific use indicated on the product’s label.”68 There have
also been instances where CIR determinations of a substance’s
safety directly conflict with other findings of significant health
concerns.69
C. Lack of Regulation of Endocrine Disruptors in
Cosmetics70
One significant health concern is chemicals that disrupt or
have the potential to disrupt the human endocrine system. These
so-called endocrine disrupting chemicals (EDCs) are synthetic
compounds71 found routinely in cosmetic products.72 Yet, EDCs

FORDHAM ENVTL. L. REV. 203, 204 (2012); Katharine A. Van Tassel & Rose H.
Goldman, The Growing Consumer Exposure to Nanotechnology in Everyday
Products: Regulating Innovative Technologies in Light of Lessons from the Past,
44 CONN. L. REV. 481, 511 (2011).
65. Myths on Cosmetics Safety, EWG'S SKIN DEEP, http://www.ewg.org/
skindeep/myths-on-cosmetics-safety/ (last visited Feb. 20, 2014).
66. See Sarah E. Schaffer, Reading Our Lips: The History of Lipstick
Regulation in Western Seats of Power, 62 FOOD & DRUG L.J. 165, 200 (2007).
67. California’s progressive and health protective cosmetics laws, known as
California’s Safe Cosmetics Act of 2005, are discussed in further in Part IV.D of
this article. See infra notes 269-74 and accompanying text.
68. CAL. HEALTH & SAFETY CODE § 111793.5(a)(2) (West 2014).
69. See, e.g., Thomas O. McGarity, Resisting Regulation with Blue Ribbon
Panels, 33 FORDHAM URB. L.J. 1157, 1190 (2006).
70. This section is reprinted in part with permission and is originally found
in-part at: Valerie J. Watnick, Our Toxics Regulatory System and Why Risk
Assessment Does Not Work: Endocrine Disrupting Chemicals as a Case in Point,
2004 UTAH L. REV. 1305, 1307-10 (2004).
71. Cassandra L. Bevan et al., The Effects of Endocrine Disrupting
Compounds on the Development of the Nervous System: Use of the Frog, Xenopus
Laevis, as a Model System, 2 VT. J. ENVTL. L. 41, 42 (2001).
72. See, e.g., Rachael Rawlins, Teething on Toxins: In Search of Regulatory
Solutions for Toys and Cosmetics, 20 FORDHAM ENVTL. L. REV. 1, 3 (2009)
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are believed by scientists to be one of the most significant manmade environmental problems of our time.73 EDCs affect the
functioning of the endocrine system74 by either blocking the effect
of naturally produced hormones in the endocrine system or by
altering the effect of naturally occurring hormones.75
The
inherent difficulty in regulating EDCs to achieve safety, or what
might be called negligible,76 or politically acceptable risk,77 is
that the science of endocrine disruption remains relatively new.78
(referring to findings of “personal-care products containing known or suspected
endocrine-disrupting chemicals”).
73. See generally THEO COLBORN ET AL., OUR STOLEN FUTURE: ARE WE
THREATENING OUR FERTILITY, INTELLIGENCE, AND SURVIVAL?—A SCIENTIFIC
DETECTIVE STORY (1996).
74. What Are Endocrine Disrupters?, EPA, http://www.epa.gov/scipoly/
oscpendo/pubs/edspoverview/whatare.htm (last visited Feb. 20, 2014) (“The
endocrine system regulates all biological processes in the body from conception
through adulthood and into old age, including the development of the brain and
nervous system, [and] the growth and function of the reproductive system . . . .”).
75. O’Brien, supra note 40, at 333. The endocrine system consists of glands,
organs, and tissues that release hormones into the human circulatory system.
The hormones carry messages that direct development and function in the
animal’s cells and organs. Hormones therefore control sexual development, both
prenatally and postnatally. Id. at 332. Commonly known EDCs include various
pesticides, polychlorinated biphenyls (PCBs), and dioxins (a byproduct of paper
production). Robin Fastenau, EPA’s Investigation and Regulation of Endocrine
Disruptors, 14 J. ENVTL. L. & LITIG. 53, 54 (1999).
76. Negligible risk is commonly considered to be the one-in-a-million chance
that an event will occur. While this seems like a small amount of risk, it takes
on a new meaning when you or someone you love is the one suffering the harm.
Additionally, these sorts of risk calculations do not account for the fact that a
typical consumer faces accumulated negligible risks from multiple toxic sources
every day. Watnick, supra note 68, at 1306 n. 8.
77. Id.
78. See, e.g., Jonathan Chevrier et al., Maternal Urinary Bisphenol A during
Pregnancy and Maternal and Neonatal Thyroid Function in the CHAMACOS
Study, 121 ENVTL. HEALTH PERSP. 138, 138-39 (2012), available at http://ehp.
niehs.nih.gov/wp-content/uploads/121/1/ehp.1205092.pdf; Fastenau, supra note
75, at 54-56 (explaining that in 1999, the EPA was entering a new phase in the
regulation of toxics by becoming more concerned about the effects of chemicals
that could potentially affect the human endocrine system as a result of the
passage of the Food Quality Protection Act of 1996 and amendments to the Safe
Drinking Water Act); Endocrine Disruptors, NAT'L INST. OF ENVTL. HEALTH SCI.,
http://www.niehs.nih.gov/health/materials/endocrine_disruptors_508.pdf#search
=endocrine (last visited Feb. 20, 2014) [hereinafter Endocrine Disruptors]. See
Safe Drinking Water Act, 42 U.S.C. §§ 300f-300j-26 (2012); Food Quality
Protection Act of 1996, Pub. L. No. 104-170, 110 Stat. 1489 (codified as amended
at various sections of 7 U.S.C. and 21 U.SC.). The EPA has stated that for the
majority of chemicals, it does not have either effects or toxicity data with regard
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EDCs are believed to work by blocking the effect of hormones or
by mimicking hormones so that the organism’s reactions are
altered.79
They are believed to “engage with the body’s
mechanism for regulating growth and development, while
sabotaging its normal functions.”80 Synthetic chemicals that act
like hormones may bind to hormone receptors just as natural
hormones would, but then interfere with the intended bodily
function.81 Alternatively, EDCs may relay molecular messages
that alter cell growth and division.82
While the exact mechanism by which EDCs cause harm is
not fully understood,83 the potential harm from EDCs is
insidious84 and well documented.85 In particular, scientists have
hypothesized that a link exists between EDCs and decreased
to endocrine disruption. 67 Fed. Reg. 79,611, 79,614 (Dec. 30, 2002). Even as to
the risk of cancer, which has been studied for many years, at least two
commentators have suggested that the use of risk analysis to draw conclusions
about cancer occurrence is limited, and subject to the application of a myriad of
estimates and assumptions. John S. Applegate & Celia Campbell-Mohn, Risk
Assessment: Science, Law and Policy, 14 NAT. RES. & ENV'T 219, 220-21 (2000).
79. O’Brien, supra note 40, at 339.
80. Sheldon Krimsky, A Clue to Understanding the Environmental Causes of
Disease, 43 ENV'T 22, 26-27 (2001), available at www.tufts.edu/~skrimsky/PDF/
environ.PDF.
81. See Krimsky, supra note 80, at 27.
82. Id.
83. JOHN WARGO, OUR CHILDREN’S TOXIC LEGACY: HOW SCIENCE AND LAW FAIL
TO PROTECT US FROM PESTICIDES 12 (1998) (noting that certain chemicals may
act as endocrine disrupters, but that the precise nature by which endocrine
disrupters operate is not known); Noah Sachs, Blocked Pathways: Potential
Legal Responses to Endocrine Disrupting Chemicals, 24 COLUM. J. ENVTL. L. 289,
290, 300 (1999) (noting that because the science of endocrine disruption is
relatively new, further research into the causal mechanism is required); see also
Leticia M. Diaz, Hormone Replacement Therapy, or Just Eat More Meat: The
Technological Hare vs. the Regulatory Tortoise, 27 B.C. ENVTL. AFF. L. REV. 391,
416 (2000).
84. See, e.g., Karen Fassuliotis, Comment, The Science of Endocrine
Disruption—Will it Change the Scope of Products Liability Claims?, 17 PACE
ENVTL. L. REV. 351, 357-60 (2000) (noting that EDCs may be a factor in
increasing rates of breast cancer, adverse reproductive trends, and decreased
functioning of the nervous system and the immune system); Phil Zahodiakin,
Hexachlorobenzene Linked to Androgen Disruption, PESTICIDE & TOXIC CHEM.
NEWS (Feb. 17, 2003) (noting that hexachlorobenzene, a known hormone
disrupter and herbicide now banned in the United States, is believed to be
present in over 95% of the U.S. population, and has adverse effects on ovarian
function).
85. See infra notes 87-88 and accompanying text.
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sperm counts, breast, testicular and prostate cancers, and
neurological disorders.86 Even more unsettling is that EDCs are
omni-present in everyday cosmetic products, in addition to
household products,87 food and beverage containers, household
pesticides, and pesticide residues on food.88
Yet, the current cosmetics regulation system in the United
States is silent on the issue of EDCs despite the fact that federal
law has begun to recognize the danger of EDCs, and in certain
areas, authorizes federal agencies to consider potential endocrine
health effects.89 The Safe Drinking Water Act, for example,
designed to improve the safety of our nation’s drinking water,
contains a general provision, which allows the EPA to regulate
where it believes a substantial population might be exposed to an
EDC.90 Likewise, the Toxic Substances Control Act allows the
EPA to regulate a chemical substance or mixture that presents an
“unreasonable risk of injury to health or the environment.”91
Conceivably, this statute could be used to regulate and protect
consumers from EDCs in cosmetics, but the reality is that the

86. Krimsky, supra note 80, at 22.
87. See generally SANDRA STEINGRABER, LIVING DOWNSTREAM: AN ECOLOGIST’S
PERSONAL INVESTIGATION OF CANCER AND THE ENVIRONMENT, 113-14, 277-78
(2010) (giving an overview of EDCs, and urging that EDCs are related to the
development of cancer, noting that phthalates, a “ubiquitous class of
petrochemicals” and a “leading suspect[] in this ransacking of manhood” are
commonly used in cosmetics).
88. Chemicals that are suspected of having adverse effects on the endocrine
system are ubiquitous.
They include: tributylin, found in paint; flame
retardants used in furniture, carpet, and electronic products; bisphenol-A, a
chemical used in the lining of food and beverage containers; phthalates, found in
plastics; pesticides; chemicals found in cosmetics; and alkyl phenols, used in
detergents. Additionally, hormone disrupting chemicals are produced when
paper is made, and in other combustion and industrial processes. These
chemicals are found in our air, and seep into our drinking water. Controversial
Issues, ENDOCRINE/ESTROGEN LETTER, http://www.eeletter.com/cntrvrsl/index.
html (last visited Feb. 20, 2014); see also, Erin Gill, Cleaning Your Home Can
Make You Ill, THE EVENING STANDARD, Nov. 25, 2003, at A26 (noting that
everyday items such as electrical goods, nonstick frying pans, and sofa and foam
seating contain chemicals that are under suspicion for endocrine disruption).
Chemicals such as PCBs, organochlorine pesticides, and brominated flame
retardants have been linked to rising rates of breast cancer, testicular cancer,
and asthma. Id.
89. See infra notes 90-96 and accompanying text.
90. 42 U.S.C. § 300j-17.
91. 15 U.S.C. § 2601(b)(2) (2012).
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EPA has infrequently used the Toxic Substances Control Act to
protect human health since its passage in 1976.92
The Food Quality Protection Act of 1996 (FQPA), often called
landmark legislation aimed at making our overall U.S. food
system safer, and amending the FDCA, specifically called for an
Estrogenic Substances Screening Program, commonly known as
the Endocrine Disruptor Screening Program (EDSP), to analyze
whether chemicals may have endocrine effects on humans.93 Yet,
the FQPA has not lived up to its overall promise, its promise as to
potential EDCs, or its promise to protect children.94 The EDSP
called for by the 1996 Act, has had little effect on how we regulate
potential EDCs in the food arena.95 More than a decade after the
passage of the FQPA, calling for an identification and assessment
of EDCs in food, the EDSP had not designated a single chemical
as an EDC.96
The FQPA requires the EPA to use Quantitative Risk
Assessment (QRA) to regulate chemicals suspected EDCs. QRA
is the process of characterizing the “potential adverse health
effects of human exposures to environmental hazards.”97 QRA

92. Holly E. Pettit, Shifting the Experiment to the Lab: Does EPA Have a
Mandatory Duty to Require Chemical Testing for Endocrine Disruption Effects
Under the Toxic Substances Control Act?, 30 ENVTL. L. 413, 424 (2000).
93. 21 U.S.C. § 346a(p).
94. See Kristina Thayer & Jane Houlihan, Pesticides, Human Health, and the
Food Quality Protection Act, 28 WM. & MARY ENVTL. L. & POL’Y REV. 257, 291303 (2004).
95. See EPA, OFFICE OF INSPECTOR GEN., REPORT NO. 11-P-0215, EPA’S
ENDOCRINE DISRUPTOR SCREENING PROGRAM SHOULD ESTABLISH MANAGEMENT
CONTROLS TO ENSURE MORE TIMELY RESULTS 9-19 (2011) [hereinafter REPORT
NO. 11-P-0215].
96. Id. at iii. As of 2011, EDSP had not formulated the Program’s goals and
priorities, or established measures to track program results. Id. Additionally,
the EDSP missed required deadlines to validate assays and to select chemicals
for priority evaluation. Id.; see also Natural Res. Def. Council v. Whitman, No.
C 99-03701 WHA, 2001 WL 1221774, at *1 (N.D. Cal. Sept. 24, 2001). The 2001
consent decree between the Natural Resources Defense Council and the EPA
required the EPA to prioritize chemicals for screening and evaluation, and to do
an initial “Tier I” screening of the 87,000 chemicals on the market that have the
potential for endocrine effects. Id. at 21-22; 63 Fed. Reg. 42,852, 42,854 (Aug.
11, 1998).
97. NAT’L RESEARCH COUNCIL, RISK ASSESSMENT IN THE FEDERAL
GOVERNMENT: MANAGING THE PROCESS 18 (1983) (commonly referred to as the
“Redbook”); see Valerie Watnick, Risk Assessment: Obfuscation of Policy
Decisions in Pesticide Regulation and the EPA’s Dismantling of the Food Quality
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appears to be a good idea on its face—a purely objective and
scientific analysis to ferret out substances that may present a
risk to human health. However, the QRA process has been
subject to serious criticism by scholars and policy makers,98
urging that the many assumptions and extrapolations involved in
risk assessments are keenly influenced by a decision maker’s
personal and political point of view.99
Risk assessment
determinations may be based on a “mixture of fact, experience
(often called intuition), and personal values that cannot be
disentangled easily.”100 Changing assumptions can result in a
risk assessment that is either more or less protective of human
health.101 An additional major limitation cited regarding QRA is
the “limited analytic resources” available to recognize and
evaluate potentially dangerous substances.102
Yet, despite the many shortcomings of QRA, there is an
argument that if a federal statute at least calls for an assessment
of risk, there begins a public recognition of some potential for risk
to humans.103 In the cosmetics arena, as discussed further below,
federal regulation does not even require identification of risk in
any serious manner, let alone risk assessment with regard to

Protection Act’s Safeguards for Children, 31 ARIZ. ST. L.J. 1315, 1332-36 (1999)
(giving a thorough discussion of QRA).
98. See, e.g., Junius C. McElveen, Jr. & Chris Amantea, Legislating Risk
Assessment, 63 U. CIN. L. REV. 1553, 1579 (1995) (noting shortcomings in the
risk assessment process, and concluding it overstates risk and provides no
additional protection); Mark Eliot Shere, The Myth of Meaningful
Environmental Risk Assessment, 19 HARV. ENVTL. L. REV. 409, 421 (1995)
(addressing the “unreliability and malleability” of risk assessments); Wendy E.
Wagner, The Science Charade in Toxic Risk Regulation, 95 COLUM. L. REV. 1613,
1625 (1995) (analyzing the complex mix of policy and science in risk assessment
decision making).
99. See Staci Jeanne Krupp, Environmental Hazards: Assessing the Risk to
Women, 12 FORDHAM ENVTL. L.J. 111, 123-24 (2000) (arguing that risk
assessments are inherently “value-laden”).
100. NAT’L RESEARCH COUNCIL, supra note 97, at 36.
101. See id. at 37.
102. See id. at 12.
103. See Jeff Gimpel, Note, The Risk Assessment and Cost Benefit Act of 1995:
Regulatory Reform and the Legislation of Science, 23 J. LEGIS. 61, 72 (1997)
(“Hazard identification is the first phase in the process of assessing risk. This
requires identifying the agent in the environment which may cause harm and
assessing the evidence which associates exposure to the agent with the resulting
harm.”).
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personal care and cosmetic product ingredients.104 Cosmetics law
in the United States instead allows manufacturers to simply state
that existing research shows that the product or ingredient is safe
to use, or to issue a statement that no determination regarding
safety has been made.105

II. THE DANGER OF EDCS AND CARCINOGENIC
SUBSTANCES IN COSMETICS, THE UNIQUE
DANGER TO CHILDREN, AND THE NEED TO
REGULATE TO PROTECT AGAINST THESE
POTENTIAL HARMS
A. The “True Burden” of Environmental Cancers is
Understated and the Specific Need to Reduce Toxic
Exposure for Children
In 2010, the President’s Cancer Panel issued a
groundbreaking report, asserting that the “true burden of
environmentally
induced
cancer
has
been
grossly
The report specifically encouraged
underestimated.”106
consumers to eat food that is not grown with synthetic pesticides,
chemical fertilizers, and growth hormones, to reduce the risk of
contracting cancer.107
The World Health Organization has
likewise estimated that by 2020, the overall rate of cancer in the

104. See supra notes 31-69 and accompanying text.
105. Id.
106. LaSalle D. Leffall, Jr. & Margaret L. Kripke, Letter to the President in
SUZANNE H. REUBEN, PRESIDENT’S CANCER PANEL, REDUCING ENVIRONMENTAL
CANCER RISK: WHAT WE CAN DO NOW (2010), available at http://deainfo.nci.
nih.gov/advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_08-09_508.pdf
[hereinafter Letter to the President].
107. SUZANNE H. REUBEN, PRESIDENT’S CANCER PANEL, REDUCING
ENVIRONMENTAL CANCER RISK: WHAT WE CAN DO NOW xx (2010), available at
http://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_
08-09_508.pdf.
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developing world will increase by 73%, and in the developed
world by 29%.108
In particular, the President’s Cancer Panel’s report also
stressed the need to reduce toxic exposure for children.109 This
report was followed by documentation in the highly respected
journal, Pediatrics, which concluded that exposure to
organophosphate pesticides, commonly used on food in the United
States,110 may be contributing to the development of Attention
Deficit Hyperactivity Disorder in children in the United States.111
These findings regarding the specific concerns for children
came as no real surprise as the National Research Council
reported, as early as 1993, that children are intrinsically more
susceptible to harm from environmental toxins.112 The National
Research Council found that physiological and biochemical
differences between adults and children make children more
susceptible to the specific effects of pesticides in the
environment.113 Experts subsequently concluded that because
they take in more air, food, and water per pound of body weight,
and because their physical bodies are still developing, children
are more susceptible generally to the effects of toxic substances in
the environment.114 And yet, two decades later, the vast majority
of our regulation of environmental toxins, including the
regulation of deleterious substances in cosmetics, does not treat
children and adults differently or even begin to address these

108. WORLD HEALTH ORG. & FOOD & AGRIC. ORG., DIET, NUTRITION AND THE
PREVENTION OF CHRONIC DISEASES 95 (2003), available at http://whqlibdoc.
who.int/trs/who_trs_916.pdf.
109. REUBEN, supra note 107, at xix.
110. Maryse F. Bouchard et al., Attention-Deficit/Hyperactivity Disorder and
Urinary Metabolites of Organophosphate Pesticides, 125 PEDIATRICS 1270, 1271
(2010), available at http://pediatrics.aappublications.org/content/early/2010/05/
17/peds.2009-3058.full.pdf+html; see Organophosphates, PESTICIDE ACTION
NETWORK, http://www.panna.org/resources/organophosphates (last visited Feb.
20, 2014) (noting that organophosphates are the most heavily used in the United
States, are toxic to the human nervous system, and are thought to be related to
the declining frog populations in California).
111. Bouchard et al., supra note 110, at 1270.
112. NAT’L RESEARCH COUNCIL, PESTICIDES IN THE DIETS OF INFANTS AND
CHILDREN 42-43 (1993).
113. See id. at 38, 42-43.
114. Cynthia F. Bearer, Environmental Health Hazards: How Children Are
Different from Adults, 5 THE FUTURE OF CHILD. 11, 11, 15, 18 (1995).
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widely acknowledged truths.115 Indeed, the FQPA is the only
federal statute to date to explicitly recognize the “unique
vulnerabilit[y]” of children to toxins in the environment.116
B. The Particular Danger in Failing to Regulate EDCs in
Cosmetics
EDCs are believed to have caused decreased fertility rates in
wildlife, and there is strong evidence that they are having a
similar effect on humans.117 Perhaps the most infamously known
case of the effects an EDC on humans involves diethylstilbestrol
(DES), a synthetic hormone with anti-androgenizing or
demasculinizing qualities,118 given to pregnant women from the
1940s to the 1970s to prevent miscarriage.119 DES did not just
affect the women taking the drug; it had multigenerational
effects, affecting her unborn fetus’ later health as an adult.120
Doctors learned that females born to mothers who were given
DES suffered reproductive abnormalities.121 These women were
also prone to a rare type of vaginal cancer.122 Additionally, males
born to mothers to whom DES was administered also suffered
reproductive abnormalities such as genital malformation and
other testicular problems.123 Our experience with DES has
115. See Philip Landrigan, HARV. SCH. OF PUB. HEALTH, http://www.hsph.
harvard.edu/faculty/philip-landrigan/ (last visited Feb. 20, 2014). The FQPA
began to address this different risk for children with regard to pesticide residues
on food by requiring increased safety mechanisms for children, including the
requirement that a special ten-times factor be applied in setting a pesticide
tolerance or limit, unless reliable evidence suggests that the existing standard
will be safe for children. 21 U.S.C. § 346a(b)(2)(C)(ii).
116. Philip Landrigan, supra note 115.
117. See COLBORN, ET AL., supra note 73, at 1-9; Keith J. Jones, Endocrine
Disrupters and Risk Assessment: Potential for a Big Mistake, 17 VILL. ENVTL.
L.J. 357, 366-67 (2006); Endocrine Disruptors, supra note 78.
118. Sachs, supra note 83, at 298.
119. Id., at 298-99; see National Environmental Health Association Position on
Endocrine Disrupters, NAT’L ENVTL. HEALTH ASSOC. (July 2, 1997), http://www.
neha.org/position_papers/PositionEndocrine.html [hereinafter NEHA Position
on EDCs].
120. Sachs, supra note 83, at 299.
121. Id.
122. Id. The rare form of cancer that afflicts females born to mothers who took
DES while pregnant is called clear-cell adenocarcinoma. Id.
123. Id. In the aftermath of the DES era, offspring of mothers who were
prescribed DES filed lawsuits against the manufacturers of the drug. Id. These
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proven that exposure to EDCs can have profound and lasting
effects on the human race.
And yet, without adequate regulation, EDCs are routinely
used in the formulation of cosmetic consumer products.124
Triclosan, for example, a chemical commonly found in hand soaps
touted to be antibacterial,125 and even in toothpastes, has been
shown to disrupt the human endocrine system.126 Additionally,
studies have shown that Triclosan affects human breast tissue.127
Another commonly found chemical in cosmetics is
oxybenzone.128
Oxybenzone, routinely used in sunscreen
products because it is believed to block ultraviolet rays, is also
believed to be an EDC.129 Public interest groups have urged that
despite its omnipresence in sunscreens, oxybenzone may cause
hormone disruption, allergies, and may actually contribute to
some skin cancers.130
Similarly, another common group of potential EDCs found in
cosmetics is the paraben group.131 Parabens, often used to
preserve product shelf life, are used in all sorts of cosmetics, from

lawsuits have resulted in the imposition of liability on manufacturers under a
market sharing theory. Id. at 334.
124. See Rawlins, supra note 72, at 1.
125. Triclosan: What Consumers Should Know, FDA, http://www.fda.gov/
forconsumers/consumerupdates/ucm205999.htm (last visited Feb. 20, 2014)
[hereinafter Triclosan].
Triclosan is also found in toothpaste, which is
worrisome since we put this directly into our mouths. Id.
126. See Triclosan, supra note 125. The FDA has not said that the use of a
soap containing Triclosan is any more beneficial to consumers than ordinary
soap and water. Id.
127. Triclosan and Triclocarbon, BREAST CANCER FUND, http://www.
breastcancerfund.org/clear-science/chemicals-glossary/triclosan.html
(last
visited Feb. 20, 2014).
128. Is Your Sunscreen in EWG’s Sunscreen Hall of Shame?, ENVTL. WORKING
GRP. (June 22, 2010), http://www.ewg.org/enviroblog/2010/06/your-sunscreenewgs-sunscreen-hall-shame [hereinafter EWG’s Sunscreen Hall of Shame].
129. Tara Parker-Pope, Sunscreen Safety is Called into Question, N.Y. TIMES,
July 22, 2008, at F5; see EWG’s Sunscreen Hall of Shame, supra note 128
(estimating that the bodies of 97% of Americans today are contaminated with
oxybenzone, which penetrates human skin).
130. CDC: Americans Carry Body Burden of Toxic Sunscreen Chemical, ENVTL.
WORKING GRP. (Mar. 25, 2008), http://www.ewg.org/news/testimony-officialcorrespondence/cdc-americans-carry-body-burden-toxic-sunscreen-chemical.
131. Parabens, BREAST CANCER FUND, http://www.breastcancerfund.org/clearscience/chemicals-glossary/parabens.html (last visited Feb. 20, 2014).
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shampoos to creams.132 In discussing parabens in cosmetics, the
FDA states that “[t]he [FDCA] does not authorize FDA to approve
cosmetic ingredients,”133 but comments that a study in 2004
found parabens in breast tumors.134 The FDA goes on to note
that these chemicals have also been found at unusual levels in
the breast tissue of women diagnosed with breast cancer,135 and
additionally, that parabens “can act similarly to estrogen.”136
However, the FDA then notes that parabens exhibit much less
intense estrogenic activity than natural estrogens, and that at
this time, consumers should not be concerned about parabens in
cosmetic products.137 The FDA goes further with this line of
rhetoric, and promises that it has continued to “evaluate new
data in this area” and that it will consider its “legal options”
under the FDCA to protect the health and welfare of
consumers.138
What is noteworthy about these statements is that the FDA
takes this position of inaction even while acknowledging that
estrogenic activity in the body is associated with breast
cancers.139 This approach to paraben regulation provides an
illustration of how hamstrung the FDA is in regulating cosmetic
ingredients and the overall U.S. regulatory approach—chemicals
are presumed safe until proven definitively guilty.140

132. Id.
133. Parabens,
FDA,
http://www.fda.gov/forconsumers/consumerupdates/
ucm128042.htm (last visited Feb. 20, 2014) [hereinafter FDA Parabens].
134. Id.
135. See id.
136. Id.
137. FDA Parabens, supra note 133.
138. Id.
139. Id. In discussing paraben research, the FDA cites a study published in
2004 (Darbre, in the Journal of Applied Toxicology) that detected parabens in
breast tumors, noting the weak estrogen-like properties of parabens, and the
influence of estrogen on breast cancer. The FDA states, “[h]owever, the study
left several questions unanswered. For example, the study did not show that
parabens cause cancer, or that they are harmful in any way, and the study did
not look at possible paraben levels in normal tissue.” Id. The FDA in these
comments assumes parabens are safe at low levels in the human body, citing an
absence of definitive proof that they cause cancer.
140. See Tiffany O’Callaghan, President’s Panel Analyzes Environmental
Cancer Impact, TIME MAG. (May 6, 2010), http://healthland.time.com/2010/05/06/
presidents-panel-analyzes-environmental-cancer-impact/.
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Perhaps one should not be surprised by this approach as we
have a long history of regulating in this regard. Cigarettes, for
example, were used without recourse and without government
warning until 1966 with the passage of the Federal Cigarette
Labeling and Advertising Act of that year.141 During the period
prior to the passage of the 1966 Act, there is much evidence that
the tobacco industry hid information from the public that
cigarettes were causative of lung cancer.142 Yet, the government
did not even begin to require warnings on cigarette packages or
otherwise warn the public of the dangers of tobacco smoking until
the 1960s.143 In essence, cigarette and tobacco use were assumed
safe for many years after they were suspected of grave harm, and
federal warnings were not mandated until definitive proof could
be offered linking cigarette smoking and cancer.
Similarly, the government hesitated to warn that
formaldehyde, a commonly used chemical in manufacturing, still
a byproduct in cosmetic formulations,144 and found today in
particle board and other wood products,145 was a danger.146 In
1982, it refused to issue a warning and label formaldehyde, a
likely human carcinogen, stating that it did not have enough
information to do so.147 It was not until 2011 that the National
141. Federal Cigarette Labeling and Advertising Act, Pub. L. No. 89-92, 79
Stat. 282 (1965) (codified at 15 U.S.C. §§ 1331-1341). The Cigarette Labeling
and Advertising Act became effective on January 1, 1966. Id. § 11.
142. See, e.g., Ingrid L. Dietsch Field, No Ifs, Ands or Butts: Big Tobacco is
Fighting for Its Life Against a New Breed of Plaintiffs Armed with Mounting
Evidence, 27 U. BALT. L. REV. 99, 120-22 (1997) (discussing evidence from
whistleblowers and others revealing that tobacco companies knew for decades of
the addictive and dangerous nature of smoking, and hid such dangers from the
public).
143. Pub. L. No. 89-92, 79 Stat. 282, 282 (1965); Matthew Baldini, The
Cigarette Battle: Anti-Smoking Proponents Go For the Knockout, 26 SETON HALL
L. REV. 348, 348 (1995) (noting that the federal government first addressed
publicly and noted the health impact of smoking in the Surgeon General’s
Advisory Committee report in 1964).
144. See supra notes 3-5 and accompanying text.
145. NAT’L TOXICOLOGY PROGRAM, U.S. DEP’T OF HEALTH & HUMAN SERVS.,
REPORT ON CARCINOGENS: FORMALDEHYDE, 195, 200 (12th ed. 2011), available at
http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/formaldehyde.pdf.
146. Id. at 201 (noting, based on an analysis of the FDA’s voluntary cosmetic
product information database, almost 20% of cosmetics contain formaldehyde or
certain formaldehyde-releasing preservatives).
147. See 47 Fed. Reg. 14366 (Apr. 2, 1982) (notice of final rule banning certain
uses of formaldehyde products, in which the Consumer Product Safety
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Institutes of Health officially determined that formaldehyde is a
known human carcinogen.148
These are just a few instances where the U.S. government
failed to regulate a potentially toxic substance in a precautionary
manner to protect human health—instances in which the
government sided with industry even in the face of mounting
evidence of harm.
Yet, EDCs in our current regulatory system present a
particularly troublesome quagmire for a number of reasons.
First, it is uniquely difficult to determine which of the more than
80,000 chemicals on the market,149 and at what exposure level,
have the potential to disrupt the human endocrine system.150
Second, these types of chemicals have the potential for
incalculable risk.151 EDCs threaten the ability of wildlife to
reproduce,152 and scientists believe they may be affecting humans
in this same vein.153
To complicate matters, as to the vast cornucopia of additional
existing chemicals and their degradation products, scientists have
not even identified all those that are EDCs.154 The EPA has
estimated that approximately 87,000 synthetic (man-made)
Commission stated that current evidence was insufficient to conclude that
formaldehyde was carcinogenic to humans).
148. NAT’L TOXICOLOGY PROGRAM, supra note 145, at 195 (formaldehyde was
listed as “reasonably anticipated to be a human carcinogen” in 1981, and its
status was changed to “known to be a human carcinogen” in 2011).
149. See Letter to the President, supra note 106. See generally H.R. 1385,
113th Cong. (2013); 2013 News Coverage, CAMPAIGN FOR SAFE COSMETICS, http://
safecosmetics.org/section.php?id=86 (last visited Feb. 21, 2014).
150. See REPORT NO. 11-P-0215, supra note 95, at iii (noting that fourteen
years after the passage of the FQPA and the Safe Drinking Water Act, the
EDSP had not determined yet whether any chemical is an endocrine disruptor);
Watnick, supra note 68, at 1314-15.
151. See REPORT NO. 11-P-0215, supra note 95, at iii.
152. See generally COLBORN ET AL., supra note 73.
153. Don Mayer, The Precautionary Principle and International Efforts to Ban
DDT, 9 S.C. ENVTL. L.J. 135, 147-48 (2002) (noting that exposure to
infinitesimal amounts of an EDC can disrupt animals’ reproductive systems);
Raphael J. Witorsch, Endocrine Disruption—History, Fact, and Fantasy of
Gender Bending Chemicals, 6 FOOD & DRUG L. INST. 32, 32 (2002) (noting a 50%
decrease in sperm production worldwide between 1940 and 1990); Fassuliotis,
supra note 84, at 357-60.
154. See Mayer, supra note 153, at 147. Scientists continue to recognize an
ever-increasing number of chemicals as EDCs. See NEHA Position on EDCs,
supra note 119.
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chemicals need to be screened155 for their potential endocrine
disrupting effects,156 and still new chemicals are developed and
marketed every day.157
In the regulation of cosmetic products, we have taken a
brazen “non-precautionary” approach—ignoring these potential
risks and avoiding regulation and required testing. It is plainly
untrue that chemicals used in cosmetics are required to be
thoroughly tested in the United States before they are sold.158
Rather, we allow industry to market chemicals to adults and
children before they are extensively tested, and then wait to see if
human health effects occur.159 Dr. Richard Clapp, a professor of
epidemiology at Boston University School of Public Health, and
one of the experts who submitted testimony contributing to the
2010 President’s Cancer Panel’s report, has said that with regard
to the current policy, “you have to wait until the bodies are
counted before you can go back and say, ‘Oh, you shouldn’t allow
people to be exposed to that chemical.’”160

155. Endocrine Disruptor Screening Program (EDSP): Endocrine Primer, EPA,
http://www.epa.gov/endo/pubs/edspoverview/primer.htm (last visited Feb. 21,
2014) (noting that the EPA has insufficient data to assess the estimated 87,000
chemicals produced today for endocrine associated effects).
156. Mayer, supra note 153, at 147-48.
157. See COLBORN ET AL., supra note 73, at 106 (“Virtually anyone willing to
put up the $2,000 for the tests will find at least 250 chemical contaminants in
his or her body fat, regardless of whether he or she lives in Gary, Indiana, or on
a remote island in the South Pacific.”); O’Brien, supra note 40, at 337 (noting
that “worldwide, 100,000 synthetic chemicals are on the market,” and that
chemical contamination and pollution is ubiquitous). One of the reasons that
synthetic chemicals are ever-present is that they often persist in the
environment and accumulate in the fatty tissue of animals. See id. Every year,
1,000 new synthetic chemicals are put on the market, most without testing for
toxic effects. Id.; see also Applegate & Campbell-Mohn, supra note 78, at 221
(purporting that variables used to calculate exposure and risk of toxics are
based on scientists’ and policymakers’ judgments and assumptions, rather than
on certainty).
158. See infra notes 159-62 and accompanying text. See generally CARL F.
CRANOR, LEGALLY POISONED: HOW THE LAW PUTS US AT RISK FROM TOXICANTS
(2011) (offering a thorough discussion of the problem with testing and lack of
cosmetics regulation).
159. Walmart Will No Longer Sell Cosmetics, Cleaners, Made with Targeted
List of Toxic Chemicals, CAMPAIGN FOR SAFE COSMETICS, http://safecosmetics.org/
article.php?id=1157 (last visited Feb. 21, 2014) (noting that Walmart has
decided to ban cosmetics with ten particularly toxic substances).
160. O’Callaghan, supra note 140.
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In a letter to President Obama that prefaced the President’s
Cancer Panel’s report, the authors point out that the nearly
80,000 chemicals on the market in the United States that are
used by millions of Americans everyday are largely untested, and
that exposure to potential environmental toxins is widespread.161
The report noted that “[o]ne such ubiquitous chemical, bisphenol
A (BPA), [a suspected EDC and carcinogen], is still found in many
consumer products and remains unregulated in the United
States, despite the growing link between BPA and several
diseases, including various cancers.”162
C. EDCs Are Difficult to Assess
Overall, the science of EDCs163 and their effect on humans is
still relatively new and in need of greater study. But the fact that
harm from them may also be dependent on an inverse bell
curve,164 meaning that lower level exposures may turn out to be
more harmful than higher exposures, suggests that these
chemicals present a particularly troubling regulatory scenario,165
especially when found in varying degrees in cosmetic products.
These chemicals simply do not lend themselves to traditional
QRA.166 Even given all of its shortcomings as an assessment tool,
QRA, by its regulatory existence, at least forces regulators (and
the public) to acknowledge, and, at the minimum, consider the
potential harm of a substance.167
With regard to EDCs, however, we are simply not
scientifically equipped to make well-educated long-term estimates
of risk from exposure to these chemicals, and this inability vexes
161. See Letter to the President, supra note 106.
162. Id.
163. The National Research Council calls EDCs “hormonally active agents,”
and the National Academies Press has published a book by this name. See
generally NAT’L RESEARCH COUNCIL, HORMONALLY ACTIVE AGENTS IN THE
ENVIRONMENT (1999). A new study, funded in part by the National Institute of
Environmental Health Sciences, also notes that exposure to BPA during
pregnancy may affect thyroid hormone levels in pregnant women and newborn
boys. See Chevrier et al., supra note 78, at 3.
164. See Endocrine Disruptors, supra note 78 (noting that small amounts of
EDCs may be problematic).
165. See Watnick, supra note 68, at 1322-23.
166. See Watnick, supra note 97, at 1334-35.
167. See Watnick, supra note 68, at 1317.
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our ability to begin to regulate them effectively.168
One
additional factor that complicates the current regulation of EDCs
is that it is not feasible to determine safe exposure levels in the
complex and interrelated world in which we live—a world in
which different individuals respond differently to different
chemical exposures and differing amounts of these exposures.169
Every day, people are exposed to multiple chemicals, some of
them suspected of endocrine disruption.170 The chemicals in our
environments may have different effects on different people,171
and the various chemicals encountered may have synergistic or
cumulative effects depending on an individual’s past exposures
and the cumulative body burden.172 The majority of our collective
research has been done in isolation—testing one chemical at a
time for its effects on living tissue—when in reality, chemicals
often act in concert.173 In real life, we are bombarded on a daily
basis with multiple chemicals in the environment,174 in our
water, and in our food. While one or more of these may exhibit
endocrine disrupting properties alone, the effects when combined
with other exposures may be synergistic and/or cumulative.175
And finally, in this complicated scenario, even if we could
determine safe exposure levels to various EDCs,176 we would then

168. See id. at 1321-23.
169. See supra notes 72-88, 163-64 and accompanying text.
170. See Watnick, supra note 97, at 1349 n. 251.
171. Id. at 1319 nn. 28-29 (noting that in performing risk assessment,
scientists consider the different effects that a substance may have on varying
individuals, often called intraspecies variation, as well as interspecies
variation).
172. See O’ Brien, supra note 40, at 348-54. Many suspected EDCs are also
persistent organic pollutants, which are not water-soluble, are stored in fat cells,
and are difficult for the human body to excrete after exposure. See RACHEL
CARSON, SILENT SPRING, 21-27, 178-80, 189-91 (1962).
173. O’Brien, supra note 40, at 350-51.
174. Toxic Substances in Our Environment, OR. HEALTH AUTH., http://public.
health.oregon.gov/HealthyEnvironments/EnvironmentalExposures/ToxicSubsta
nces/Pages/index.aspx (last visited Feb. 21, 2014); see O’Brien, supra note 40, at
348-51.
175. Mary L. Lyndon, The Toxicity of Low-Dose Chemical Exposures: A Status
Report and a Proposal, 52 JURIMETRICS 457, 475 (2012) (reviewing CARL F.
CRANOR, LEGALLY POISONED: HOW THE LAW PUTS US AT RISK FROM TOXICANTS
(2011)).
176. See supra notes 149-57, 163-75 and accompanying text.
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have the enormously difficult task of ensuring compliance with
these pre-determined “safe” exposure levels.
III. “GAPING HOLES” IN U.S. COSMETICS
LEGISLATION AND PROPOSALS FOR CHANGE
A. The Current FDA Regulations on Cosmetic Products
Are Too Lax and Contain “Gaping Holes”
a.

Pre-approval of Cosmetic Ingredients is Lacking

The FDA does not pre-approve cosmetic products or
ingredients before distribution.177 Although FDA regulations
state that “[e]ach ingredient used in a cosmetic product and each
finished cosmetic product shall be adequately substantiated for
safety prior to marketing,” the inclusion of a warning simply
noting that “[t]he safety of this product has not been determined”
is sufficient to allow a manufacturer to legally distribute the
product.178 There is, therefore, no prospective determination, as
there is under the new European Union regulations179 that a
product formulation or ingredient is safe. Rather, in the absence
of data, all cosmetic products and formulations are presumed safe
until definitely proven otherwise.
With limited exceptions,
manufacturers can use any ingredient in their product as long as
the ingredient and the cosmetic product are safe (or the lack of a
safety determination is noted), the product is properly labeled,
and does not otherwise constitute an “adulterated” or
“mislabeled” product under the FDCA.180 Additional regulations
set up voluntary programs for the registration of cosmetic product
manufacturers181 and of cosmetic ingredient statements.182

177. Cosmetics: FDA Authority over Cosmetics, FDA, (Aug. 3, 2013), http://
www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ucm074162
.htm.
178. 21 C.F.R. § 740.10(a).
179. See infra notes 216, 226-30 and accompanying text.
180. Id.
181. See 21 C.F.R. §§ 710.1-710.9.
182. See id. §§ 720.1-720.9.
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Although a series of FDA regulations do prohibit or restrict
the use of certain limited ingredients in cosmetic products,183 the
regulations overall rely too heavily on voluntary industry efforts
and contain huge loopholes.184 For example, existing regulations
provide a process for manufacturers to request that certain
cosmetic ingredients be kept confidential as proprietary data,185
data that the makers then do not need to list on a cosmetic
ingredient list.186 Manufacturers thus do not have to disclose all
of the ingredients in their products if they bury certain
ingredients in proprietary information, using ingredient code
words such as “fragrance” or “flavor.”187 These one-word phrases
are often allowed in place of the actual list of ingredients that
make up the fragrance or flavor.188
Moreover, there is absolutely no incentive for a manufacturer
to test its product ingredients for ill health effects, including
endocrine, carcinogenic, reproductive, or neurotoxic effects, even
though the manufacturer is in the best position to do so.189 Such
183. See id. §§ 700.11, 700.13, 700.14, 700.15, 700.16, 700.18, 700.19, 700.23,
700.27 (regulating bithionol, mercury, vinyl chloride, halogenated
salicylanilides, zirconium, chloroform, methylene chloride, chlorofluorocarbons,
and certain cattle materials at heightened risk of infection with bovine
spongiform encephalopathy, respectively).
184. See supra notes 37-40, 64-69 and accompanying text; see infra notes 327,
331-37 and accompanying text.
185. The listed factors to determine whether an ingredient qualifies as a
confidential trade secret are:
(1) The extent to which the identity of the ingredient is known
outside petitioner's business; (2) [t]he extent to which the identity of
the ingredient is known by employees and others involved in
petitioner's business; (3) [t]he extent of measures taken by the
petitioner to guard the secrecy of the information; (4) [t]he value of
the information about the identity of the claimed trade secret
ingredient to the petitioner and to its competitors; (5) [t]he amount
of effort or money expended by petitioner in developing the
ingredient; and (6) [t]he ease or difficulty with which the identity of
the ingredient could be properly acquired or duplicated by others.
21 C.F.R. § 720.8(b).
186. Id. § 701.3(a).
187. Id.
188. See id.
189. See, e.g., Pine St. Trading Corp. v. Farrell Lines, Inc., 364 A.2d 1103,
1109 (Md. 1976) (noting that the government has the burden to prove a product
is dangerous in an condemnation action); United States v. Wash. Dehydrated
Food Co., 89 F.2d 606, 608 (8th Cir. 1937) (noting that the government’s burden
of proof is the same as under the former Pure Food and Drug Act).
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testing, if conducted at the manufacturer’s expense, might lead
the FDA to determine that a product is adulterated or
misbranded, and to therefore prohibit the sale and distribution of
the product.190 A cosmetics manufacturer is better served in
terms of marketing its product most efficiently—although
perhaps not most ethically—to simply state that a product lacks
appropriate safety data or proof of efficacy prior to manufacturing
and sale.191 To begin to protect human health, Congress must
pass legislation requiring pre-market safety testing of cosmetics
ingredients and products.192
b.

The FDA Must Have Recall Power Based on the
Reasonable Belief that a Substance is Harmful

The FDA currently does not have authority to require a
mandatory recall of cosmetics.193 This lack of recall power, and
the manner in which it severely hampers FDA regulatory efforts,
has been the cause of much consternation among consumers,
activists, and congressional staff seeking more rigorous
regulation of cosmetics.194 The FDA has no general power of
recall—it may only require recall where a court action is
instituted and upheld against a mislabeled or adulterated
product, thereby allowing the seizure of such product.195

190. See Wendy E. Wagner, Choosing Ignorance in the Manufacture of Toxic
Products, 82 CORNELL L. REV. 773, 775 (1997) (noting that “[a] manufacturer
that conducts no research can generally avoid liability because plaintiffs and
government research programs are unlikely to conduct scientific research on
their own”).
191. See Wagner, supra note 190, at 775.
192. See supra notes 37-40, 64-69 and accompanying text.
193. Id.
194. See, e.g., Victoria Farren, Note, Removing the Wrinkle in Cosmetics and
Drug Regulation: A Notice Rating System and Education Proposal for AntiAging Cosmeceuticals, 16 ELDER L.J. 375, 393 (2009).
195. 21 C.F.R. § 7.40(a), (c) (2014) (“(a) Recall . . . [of] consumer products that
are in violation of laws administered by the [FDA] . . . is a voluntary action. . . .
(c) [S]eizure . . . or other court action is indicated when a firm refuses to
undertake a recall requested by the [FDA] . . . .”). Only through court action can
the FDA mandatorily seize and stop the distribution of unsafe cosmetics. See 21
U.S.C. § 334(a); see also United States v. Eight Unlabeled Cases, 888 F.2d 945,
946, 949 (2d Cir. 1989) (affirming the FDA’s forfeiture and condemnation action
regarding an adulterated cosmetic product).
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Cosmetics Regulation Must Account for the LongTerm Effects of Exposure

Perhaps the most worrisome failure of our toxics regulatory
system in general, and with regard to cosmetics in particular, is
that it makes no meaningful accounting for the long-term effects
of consumer products on human health.196 EDCs in particular
have been shown to have long-lasting, intergenerational
effects,197 as well as associations with cancer in future
generations many decades after exposure.198
d.

Cosmetics Regulation Must Account for the
Differences Between Adults and Children

Our regulation of cosmetics also does not address concerns
specific to children. The news over toxic chemicals in baby
shampoo highlights the fact that cosmetic products designed for
children are not subject to rigorous regulation.199 Children are
particularly susceptible to toxins in cosmetic products, as they
take in more air and water per pound of body weight,200 and have
longer future lives to carry the burden of persistent chemicals in
their bodies.201 Additionally, they have immature skin that may
be more receptive to the absorption of toxins.202 Revised health
protective cosmetics regulations would take the differences
between adults and children into account, and would provide for
more health protective regulation in products designed for use on
children and babies.
e.

Consumers Have a False Sense of Security

Finally, the biggest mistake in our cosmetic regulation
paradigm may be that it gives consumers a false sense of security.
Many consumers likely believe that the FDA exerts strong and

196.
197.
198.
199.
200.
201.
202.

See supra notes 37-40 and accompanying text.
See supra notes 70-88 and accompanying text.
See supra notes 83-88 and accompanying text.
See supra notes 1-9 and accompanying text.
See supra notes 109-116 and accompanying text.
CRANOR, supra note 158, at 102-03.
Id. at 103.
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powerful authority over cosmetic manufacturers.203 Consumers
would likely be shocked to learn that the FDA barely has the
power to recall a cosmetic product suspected of potential harm.
Yet, consumers see federal regulation in place, and they may
assume that all that is in their drugstore is safe. The very
existence of federal regulation, coupled with perceived FDA
oversight, and the FDA’s actual lack of strong regulatory
authority likely gives consumers an unwarranted and false sense
of security that lulls the populace into complacency.
f.

Nanoparticles Are Not Regulated

Other than the recent and somewhat limited amendment to
the FDCA, that merely encourages the FDA to further scientific
study of nanomaterials,204 there are no provisions under current
U.S. law or regulation that begin to fully address health concerns
over nanotechnology in consumer products. As noted above,
manufacturers have no financial incentive to study
nanotechnology, but can continue to market and sell these
formulations in the absence of information that they are harmful
to human health.205
The use of such particles should be
disallowed pending safety studies, but at the very least, federal
regulations must require labeling of products containing
nanoparticles so that consumers can make informed decisions
about whether to choose such products.
B. The Normative Goal Must Shift in How We Regulate
Consumer Products to Protect Human Health and the
Environment
The idea that “[w]e can and should develop and apply
standards that ensure safety to human health in our toxics

203. As far back as the 1960s, the public seemed to believe that the
government was protecting “us.” See CARSON, supra note 172, at 181 (“To the
question, ‘But doesn’t the government protect us from [pesticide
contamination]?’ the answer is, ‘Only to a limited extent.’”) (noting that in that
time period, the activities of the FDA were severely hampered by a lack of
resources, and that state laws were not protective).
204. See supra notes 49-55 and accompanying text.
205. See id.
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regulatory schemes,”206 including as they relate to cosmetics and
other consumer products, does not have solid basis in the political
and scientific reality of the current world.207 Rather, our efforts
are directed at regulating to achieve a level of risk that is
“politically acceptable.”208
Indeed, since consumers seem
unaware of the FDA’s lack of authority and real oversight in the
cosmetics arena, and even assume stringent federal regulation,209
it seems obvious from a political point of view, for politicians to
continue to endorse this loose cosmetics regulatory system. In
place of strong federal oversight, the cosmetics industry is instead
largely allowed to self-police and market most products as they
see fit, absent some showing by the public of clear potential for
human harm.210
Even if safety were the true goal of toxics regulation and the
regulation of cosmetic products, the creation of safety-based
standards to regulate toxins is not a practical goal.211 There exist
206. Watnick, supra note 68, at 1305. Both the Clean Air Act and the Safe
Drinking Water Act require the measurement of risk through the process of risk
assessment and risk management. See Applegate & Campbell-Mohn, supra
note 78, at 222 (noting that risk assessment has come to dominate Congress’
approach to toxics regulation).
207. Watnick, supra note 68, at 1305-06.
208. It is fair to note that the change in emphasis in toxics regulation from
safety to acceptable risk occurred fairly recently in the 1980s as the regulatory
system became solidly based on risk assessment. See supra notes 98-102 and
accompanying text. The author would assert however, that the public is
unaware of this dramatic shift in regulatory emphasis. Indeed, I have argued in
the past that politicians and regulators achieve regulatory obfuscation by using
terminology and standards that imply safety, using QRA where mandated, and
stating that risk levels are negligible:
For example, the FQPA states that all tolerances must be “safe.” 21
U.S.C. § 346a.
However, “safe” means that there exists a
“reasonable certainty that no harm will result from aggregate
exposure” to the pesticide residues from food and other exposures, id.
§ 346a(b)(2)(A)(ii), and this is generally assumed to mean that there
exists a one-in-one-million chance that an effect will occur. Cf. Jay
Michaelson, Rethinking Regulatory Reform: Toxics, Politics and
Ethics, 105 YALE L.J. 1891, 1899 (1996). [. . .] This negligible risk
standard is designed in keeping with the assumption that our food
supply is not ever one hundred percent safe. See id. The one-in-onemillion standard might be deemed politically acceptable risk.
Watnick, supra note 68, at 1306 n. 8.
209. See Wagner, supra note 190, at 774.
210. See supra notes 56-69 and accompanying text.
211. See Watnick, supra note 68, at 1307.
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over 80,000 chemicals on the market today, the vast majority of
which have not been tested for endocrine or other toxic effects.212
If we are to regulate these chemicals from a more health
protective stance, our thinking on how we regulate synthetic
substances—and especially those marketed for everyday
consumer use—must change.
Toward such ends, the
precautionary principle mandates that when a substance is
suspected of harm to human health, the substance is heavily
regulated and restricted, until evidence is available to indicate
that the product is not a danger to human health.213 Under a
new norm in line with the precautionary principle, products and
synthetic chemicals would not be given the benefit of the doubt—
they would not be “presumed innocent until proven guilty,” as
under the current system. This type of approach would be more
consistent with those adopted in Europe and Canada, and more
health protective.
IV. FOREIGN AND STATE-LEVEL COSMETICS
REGULATION
A. European Cosmetics Regulation
The European Union (EU)214 began regulating cosmetics in
1976 through the Cosmetics Directive.215 Overall, the Cosmetics
Directive is far more protective of human health than U.S.
regulation. While the EU’s labeling requirements are largely in
line with U.S. requirements,216 new EU regulations now go so far
as to require some prospective safety findings, and also prohibit
certain ingredients in cosmetics.
The original EU Cosmetics Directive requires that cosmetic
products “must not cause damage to human health when applied
212. See Letter to the President, supra note 106.
213. See John S. Applegate, The Taming of the Precautionary Principle, 27
WM. & MARY ENVTL. L. & POL’Y REV. 13, 13 (2002).
214. Frequently Asked Questions (FAQ), COUNCIL OF THE EUROPEAN UNION,
http://www.consilium.europa.eu/contacts/faq?lang=en&faqid=79264 (last visited
Feb. 21, 2014) (noting that the EU was known as the European Community
until 1993).
215. See generally Council Directive 76/768, 1976 O.J. (L 262) 12 (EC)
[hereinafter EU Cosmetics Directive].
216. Id. art. 6.
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under normal or reasonably foreseeable conditions of use, taking
account . . . the product’s presentation, its labeling, any
instructions for its use and disposal as well as any other
indication or information provided by the manufacturer . . . .”217
The Cosmetics Directive further states that the inclusion of a
warning label does not exempt a manufacturer or product from
any requirements under the Cosmetics Directive.218
The
Cosmetics Directive includes listings of prohibited ingredients,
restricted ingredients, as well as permitted colorants,
preservatives, and ultraviolet filters.219 Prohibited ingredients
include those that are “carcinogenic, mutagenic or toxic for
reproduction” pursuant to the EU’s Dangerous Substances
Directive.220 The Cosmetics Directive also requires cosmetics
manufacturers to make the following information available for
government regulators: (1) the composition of the product; (2) the
“physico-chemical and microbiological specifications” of all
ingredients and the final product; (3) the method of manufacture
of the product; (4) information regarding the assessment of the
product’s safety for human health; (5) data on adverse health
effects from the use of the product; (6) proof of the product’s
effectiveness; and (7) information on any animal testing relating
to the product.221 A country in the EU may ban or restrict the

217. Id. art. 2.
218. Compare EU Cosmetics Directive, supra note 215 with 21 C.F.R. §
740.10(a) (providing that a warning label allows the distribution of a product
even if it has not yet been substantiated as safe).
219. EU Cosmetics Directive, supra note 215, art. 4; JAN VERNON & TOBE A.
NWAOGU, RISK & POL’Y ANALYSTS LTD., COMPARATIVE STUDY ON COSMETICS
LEGISLATION IN THE EU AND OTHER PRINCIPAL MARKETS WITH SPECIAL ATTENTION
TO SO-CALLED BORDERLINE PRODUCTS 20 (2004), available at http://www.pedz.
uni-mannheim.de/daten/edz-h/gdb/04/j457_-_final_report_-_cosmetics.pdf
(noting over 400 items on the prohibited list).
220. EU Cosmetics Directive, supra note 215, art. 4b.
221. Id. art. 7a (noting that with respect to information relating to the
product’s safety, the manufacturer “shall take into consideration the general
toxicological profile of the ingredients, their chemical structure and their level of
exposure,” taking particular account of “the specific exposure characteristics of
the areas on which the product will be applied or of the population for which it is
intended”).
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distribution of a product upon receiving information that such
product represents a health hazard.222
In 2009, the European Parliament and Council further
strengthened the health protectiveness of the Cosmetics
Directive.223 The new regulation, effective July 11, 2013, with
some provisions in effect earlier,224 called the New Cosmetics
Regulation, provides that manufacturers—or importers, as
applicable—must take immediate corrective measures to rectify
non-conformity with the regulation, including withdrawing or
recalling affected products, and immediately informing national
regulators when a product presents a health risk.225
The real meat of the New Cosmetics Regulation is that prior
to marketing a cosmetic product, a manufacturer must assess the
safety of the product, and establish a cosmetic product safety
Information must be provided to the European
report.226
Commission, including the presence of any nanomaterials—and
their expected exposure conditions—and substances classified as
“carcinogenic, mutagenic, or toxic for reproduction.”227 Under the
New Cosmetics Regulation, manufacturers—or importers—shall
maintain a product information file containing safety information
on each product for a period of ten years following the date that

222. Id. art. 12. The Cosmetics Directive also contains a ban on products that
involved testing on animals, id. art 4a, and requires that an inventory of
ingredients used in cosmetics be compiled and published. Id. art. 5a.
223. See generally Regulation 1223/2009, of the European Parliament and of
the Council of 30 Nov. 2009 on cosmetic products, 2009 O.J. (L 352) 59
[hereinafter EU Cosmetics Regulation].
224. EU Cosmetics Regulation, supra note 223, art. 40.
225. Id. art. 5.2. Distributors face obligations similar to importers and
manufacturers of cosmetics. Id. art. 6. Manufacturers must always comply with
good manufacturing practices. Id. art. 8. Compliance is presumed when
processes comply with harmonized standards, as referenced in the EU’s official
journal. Id. art. 8.2.
226. See id. art. 10.1, 13.1.
227. Id. art. 13.1(f), (g).
The New Cosmetics Regulation defines
“nanomaterial” as “an insoluble or biopersistant and intentionally manufactured
material with one or more external dimensions, or an internal structure, on the
scale from 1 to 100 nm.” Id. art. 2.1(k). The definition of “nanomaterials” will
be adjusted in accordance with technical and scientific developments in the
nanotechnology field. Id. art. 2.3.
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the last batch of product was placed on the market, and shall
make this information available to national regulators.228
This requirement of prospective safety information markedly
contrasts with current U.S. regulations, pursuant to which a
product is presumed safe unless information exists to suggest
otherwise. Additionally, the New Cosmetics Regulation calls for
identification of EDCs in cosmetic products on an expedited basis.
While the New Cosmetics Regulation continues the categorization
of materials with permitted, restricted, and prohibited
designations,229 it provides for the amendment of an existing
categorization when substances are identified as EDCs.230
The New Cosmetics Regulation also takes a proactive
approach concerning nanomaterials in cosmetics.231 It states that
“[f]or every cosmetic product that contains nanomaterials, a high
level of protection of human health shall be ensured.”232 The
regulation requires manufacturers to identify: (1) the “size of
particles, physical and chemical properties” of the nanomaterials;
(2) an estimated amount of nanomaterials in cosmetics to be
marketed per year; (3) the toxicological profile of the
nanomaterial; (4) safety data of the nanomaterial; and (5)
“reasonably foreseeable exposure conditions.”233 Where there is a
potential risk to human health regarding nanomaterials,
including when there is insufficient data available, the European
Commission may add such materials to the restricted or
prohibited ingredient lists.234 Additionally, the regulation calls
for the European Commission to make available to the public, by
January 11, 2014, a list of all nanomaterials used in cosmetic
products placed on the market.235

228. Id. art. 11 (requiring the product information file to contain information
similar to that required under the Article 7a of the Cosmetics Directive). See
EU Cosmetics Directive, supra note 215, art. 7a.
229. EU Cosmetics Regulation, supra note 223, art. 14.1(a)-(b). The New
Cosmetics Regulation also continues the ban on animal testing, and contains
similar product labeling requirements as in the Cosmetics Directive. Id. art.
18.1, 19.1.
230. Id. art. 15.4.
231. Id. art. 16.1.
232. Id.
233. Id. art. 16.3.
234. Id. art. 16.6.
235. EU Cosmetics Regulation, supra note 223, art. 16.10(a).
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Moreover the manufacturer, importer and/or distributor are
also required to report “serious undesirable effects” to the
relevant national regulator.236 When there is serious doubt
concerning the safety of a substance contained in cosmetics,
national regulators may request from manufacturers or importers
a list of all their products containing such substance.237
Regulators may likewise require the manufacturer to
withdraw or recall products for failure to comply with the New
Cosmetics Regulation.238 Such withdrawal or recall may be
enforced if necessary to prevent serious health risk or if the
manufacturer does not do so voluntarily.239
Overall, while not entirely of the long-term view, the EU’s
cosmetic regulations take a prospective and cautionary stance
toward protecting human health.240 In calling for disclosure of
ingredient usage, such as the usage of nanomaterials241 or
suspected endocrine disrupting chemicals242 in cosmetics,
requiring prospective safety information, and providing the
government with the ability to recall and force the withdrawal of
products where there is doubt concerning the safety of a
product,243 the EU’s New Cosmetics Regulation is decidedly more
health protective than existing U.S. regulations. In all of the
aforementioned ways, the New Cosmetics Regulation contrasts

236. Id. art. 23.1. “Undesirable effect” is defined as “an adverse reaction for
human health attributable to the normal or reasonably foreseeable use of a
cosmetic product,” while “serious undesirable effect” is “an undesirable effect
which results in temporary or permanent functional incapacity, disability,
hospitalization, congenital anomalies or an immediate vital risk or death.” Id.
art. 2.1(o)-(p).
237. Id. art. 24.
238. EU Cosmetics Regulation, supra note 223, art. 25.1.
239. Id. art. 25.5(a)-(b).
240. See id. art. 23. New Zealand cosmetic regulations are loosely based on
the EU regulations, calling for the classification of product ingredients. See
Cosmetic Products Regulations Updated, ENVTL. PROT. AUTH., (June 29, 2012),
http://www.epa.govt.nz/news/erma-media-releases/Pages/Cosmetic-Productsregulations-updated.aspx (N.Z.). See generally HAZARDOUS SUBSTANCES AND
NEW ORGANISMS ACT 1996, ENVTL. PROT. AUTH. (2012) (N.Z.), available at
http://www.epa.govt.nz/Publications/Cosmetic%20Products%20Group%20Standa
rd.pdf.
241. EU Cosmetics Regulation, supra note 223, art. 16.10(a).
242. Id. art. 15.4.
243. See id. art. 25.1.
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markedly with the lack of such provisions and FDA authority in
the United States.244
B. Canadian Cosmetics Regulation
Under the Canadian Food and Drugs Act,245 prohibited
cosmetics are those: (1) containing “any substance that may cause
injury to the health of the user . . . [or] any filthy or decomposed
substance,” or (2) which were “manufactured, prepared,
preserved, packaged or stored under unsanitary conditions.”246
While these regulations at first glance seem similar to U.S.
cosmetics regulation, the Canadian regulations actually take a
more health protective stance. Canadian regulations247 prohibit
the sale of cosmetics containing an estrogenic substance.248
Health Canada, the Canadian federal regulator with authority
over cosmetics, also prepares and updates a Cosmetics Ingredient
Hotlist, which notes ingredients that are either prohibited or
restricted from use in cosmetic products.249
Importantly, the Canadian regulations allow the government
to request that a manufacturer submit evidence of a cosmetic
product’s safety, and to require the halting of sales if such
information is not provided or is incomplete.250 The Canadian
regulations also require manufacturers and importers to
promptly file with the government information about the
manufacture and composition of a cosmetic product within ten
days of first selling the product.251 As expected, the Canadian
cosmetic regulations contain general labeling requirements, but
additionally, the Canadian regulations also prohibit, without
evidence, labeling claims about: “(a) the ability of the cosmetic or
any of its ingredients to influence the chemistry of the skin, hair
or teeth; or (b) the formulation, manufacture or performance of
244.
245.
246.
247.
248.
249.

See supra notes 177-205 and accompanying text.
See generally Food and Drugs Act, R.S.C. 1985, c. F-27 (Can.).
Id. § 16.
See generally Cosmetic Regulations, C.R.C., c. 869 (Can.).
Id. § 15(b).
List of Prohibited and Restricted Cosmetic Ingredients (“Hotlist”), HEALTH
CANADA,
http://www.hc-sc.gc.ca/cps-spc/cosmet-person/indust/hot-list-critique/
index-eng.php (last visited Feb. 21, 2014).
250. C.R.C., c. 869, § 29 (Can.).
251. Id. § 30.
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the cosmetic that would imply that the user . . . will not suffer
injury to their health.”252
C. Regulation of Cosmetics in Japan
Cosmetic products in Japan are regulated under the
Pharmaceutical Affairs Law, which was first enacted in 1943.253
Prior to 2001, manufacturers and importers had to obtain premarket approval for every ingredient used in a cosmetic product
from the Ministry of Health, Labor and Welfare.254 Following a
deregulation of the cosmetics industry, making the Japanese
system a mirror of the U.S. system,255 manufacturers and
importers now merely need to notify the government of the
product’s brand name prior to distribution.256 The revised
Japanese cosmetics regulatory system still requires pre-approval
for the use of certain types of ingredients (e.g. colorants,
preservatives, and ultraviolet filters),257 and other chemicals not
subject to pre-approval may be disallowed or only allowed on the
condition that they are sold with safe use instructions or warning
labels after government review.258
D. State Regulation of Cosmetics—California
In 1986, Californian voters supported ballot proposal
Proposition 65, under the Safe Drinking Water and Toxic
Enforcement Act, to regulate chemicals in drinking water and
Although
toxic substances in the general environment.259
Proposition 65 is not directed specifically at cosmetic products, it

252. Id. § 21.1. Health Canada can request that such evidence by submitted to
it by the manufacturer. Id. § 21.2.
253. VERNON & NWAOGU, supra note 219, at 27-28; see Giovanni Pisacane,
Cosmetics Market Regulation in Asian Countries, 4 HOUSEHOLD & PERSONAL
CARE TODAY 21 (2009), available at http://www.greatwaylimited.com/admin/
upload/Cosmetic%20market%20regulation%20in%20Asian%20Countries.pdf.
254. VERNON & NWAOGU, supra note 219, at 29.
255. See id.
256. Id.
257. Janet Winter Blaschke, Globalization of Cosmetic Regulations, 60 FOOD &
DRUG L.J. 413, 414-15 (2005).
258. See id. at 415.
259. See Proposition 65, OFFICE OF ENVTL. HEALTH HAZARD ASSESSMENT,
http://www.oehha.org/prop65. html (last visited Feb. 21, 2014).
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regulates certain chemicals found in cosmetics. Proposition 65 is,
to the author’s knowledge, the most stringent health protective
toxic substances regulation in the United States.
Proposition 65 prohibits the discharge of chemicals known to
cause cancer or reproductive toxicity into the water,260 and
requires that products containing these chemicals contain a
warning label.261 Consumer products, including cosmetics, which
contain materials included on the list of hazardous chemicals in
Proposition 65, are required to include one of the following
warnings: “WARNING: This product contains a chemical known
to the State of California to cause cancer” or “WARNING: This
product contains a chemical known to the State of California to
cause birth defects or other reproductive harm.”262
Proposition 65 also requires California to publish an annual
list of chemicals that cause cancer or reproductive toxicity.263
Pursuant to Proposition 65, California thus established the
Carcinogenic Identification Committee and the Developmental
and Reproductive Toxicant Identification Committee,264 both to
determine whether chemicals have been found to cause cancer or
reproductive toxicity,265 and also to identify federal and
international bodies whose findings may be considered as
authoritative.266
Proposition 65 has thus required stricter, more health
protective regulation of cosmetics in California. California’s
Office of Environmental Health Hazard Assessment, which
administers the Proposition 65 provisions, for example, lists
toluene, found often in nail care products, on the annual list of
hazardous chemicals for which labels are required to warn that
the chemical
“causes birth defects or other reproductive
harm.”267

260. CAL. HEALTH & SAFETY CODE § 25249.5 (West 2014).
261. Id. § 25249.6.
262. CAL. CODE REGS. tit. 27, § 25603.2 (2014).
263. CAL. HEALTH & SAFETY CODE § 25249.8(a).
264. CAL. CODE REGS. tit. 27, § 25302.
265. Id. § 25305.
266. Id. § 25306. The EPA and the FDA are among the regulatory and other
bodies that have been identified as authoritative. Id. § 25306(l)-(m).
267. PROPOSITION 65 IN PLAIN LANGUAGE!, OFFICE OF ENVTL. HEALTH HAZARD
ASSESSMENT 4 (2013), available at http://www.oehha.org/prop65/pdf/P65Plain.
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In 2005, the California Legislature furthered the health
protective initiative of Proposition 65 by enacting the California
Safe Cosmetics Act (CSCA).268 Under the CSCA, California’s
Department of Public Health runs the California Safe Cosmetics
Program.269 The Safe Cosmetics Program compiles a list of all
chemicals known or suspected of causing cancer, birth defects, or
reproductive harm, and maintains a publicly available database
containing ingredient information.270
Central to the CSCA is also the requirement that cosmetics
manufacturers report to the State Department of Public Health
any products containing “any ingredient that is a chemical
identified as causing cancer271 or reproductive toxicity.”272 The
CSCA specifically requires that ingredients listed as “fragrance,”
“flavoring,” “other ingredient,” or ingredients otherwise treated as
a trade secret under federal regulations, must be identified and
listed.273
With respect to cosmetics marketed as containing “organic”
products, regulations under California’s Organic Products Act of

pdf. The Proposition 65 list now contains approximately 800 substances. Id. at
1.
268. Amity Hartman, FDA’s Minimal Regulation of Cosmetics and the Daring
Claims of Cosmetic Companies That Cause Consumers Economic Harm, 36 W.
ST. U. L. REV. 53, 68-69 (2008); see CAL. HEALTH & SAFETY CODE §§ 111791111793.5.
269. California Safe Cosmetics Program, CAL. DEP’T OF PUB. HEALTH,
http://www.cdph.ca.gov/programs/cosmetics/Pages/default.aspx (last visited Feb.
21, 2014) [hereinafter California Safe Cosmetics Program].
270. California Safe Cosmetics Program, supra note 269.
271. The CSCA defines “[c]hemical identified as causing cancer or
reproductive toxicity” as a substance: (1) “known or reasonably anticipated to be
a human carcinogen in a National Toxicology Report on carcinogens”; (2)
evaluated to be a carcinogen by the International Agency for Research on
Cancer; (3) identified as a known or likely carcinogen by the EPA; or (4) a
“substance identified as having some or clear evidence of adverse
developmental, male reproductive, or female reproductive toxicity effects in a
report by an expert panel of the National Toxicology Program’s Center for the
Evaluation of Risks to Human Reproduction.” CAL. HEALTH & SAFETY CODE §
111791.5(b)(1)-(4).
272. Id. § 111792(a); Hartman, supra note 268, at 69. Manufacturers with less
than $1 million of cosmetics sales within and outside of California would not be
subject to the requirement to report the use of materials that cause cancer or
have reproductive toxicity. CAL. HEALTH & SAFETY CODE § 111792(d).
273. CAL. HEALTH & SAFETY CODE § 111792(a)(1)-(2).

https://digitalcommons.pace.edu/pelr/vol31/iss3/1

42

2014]

U.S. REGULATION OF COSMETIC PRODUCTS

637

2003274 have been promulgated requiring that cosmetic products
with labels stating “organic” must have “at least 70% organically
produced ingredients.”275 In contrast, neither federal law nor
FDA regulations police the meanings of the terms “natural” or
“organic” with respect to cosmetic products.276
V. PROSPECTIVE U.S. REGULATION
A. Federal Proposals: Mistakes from the Past
Current proposals to improve the safety of U.S. cosmetics
regulation generally do not go far enough to effect changes in the
overall regulatory paradigm.277 They continue to operate from
the stance that a chemical or product formulation is safe until
proven otherwise.278 Several new proposals for federal law in
recent years have, however, attempted to strengthen U.S.
cosmetics regulation within the existing toxics regulation
paradigm. The Safe Cosmetics and Personal Care Products Act,
introduced by Congresswoman Jan Schakowsky (D-Ill.) and
currently in committee, goes furthest, requiring prospective
safety information, prior to the marketing of a cosmetic
product.279
The proposed Enhancement Act, introduced in 2012,280 would
have amended the FDCA to require the registration of cosmetic
products and cosmetic manufacturing facilities.281 A facility’s
registration would have been subject to suspension for violations
of the FDCA if such violations could have resulted in serious
adverse health consequences or death to humans or animals.282

274. See id. §§ 110810-110959.
275. Hartman, supra note 268, at 70 (internal quotation marks omitted).
276. See id.
277. See infra notes 279-364 and accompanying text.
278. Id.
279. See H.R. 1385, 113th Cong. (2013); infra notes 319-364 and accompanying
text.
280. See H.R. 4262, 112th Cong. (2012). Rep. Frank Pallone, Jr. (D-N.J.)
introduced the Enhancement Act, and the bill was referred to the House
Committee on Energy and Commerce on March 26, 2012. Id.
281. Id. § 2(c).
282. Id.
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The Enhancement Act boldly called for cosmetic
manufacturers to establish a file of scientific evidence
demonstrating a product’s safety before introducing the cosmetic
product into commerce.283 It defined “safe” as “evidence in the
file established [pursuant to the Enhancement Act]
demonstrat[ing] that there is a reasonable certainty that no harm
will result from the use of the cosmetic product under the
intended conditions of use for such cosmetic product.”284
Manufacturers, packers and distributers would have also
been required to submit to the FDA, within fifteen business days
of receipt, reports of any serious adverse event which they
received regarding the use of their cosmetics in the United States,
and to have maintained records of all information about serious
adverse effects for a period of six years.285 For this purpose, the
Enhancement Act defined “serious” as: “(A) resulting in—(i)
death; (ii) a life-threatening experience; (iii) inpatient
hospitalization; (iv) a disability, disfigurement, or incapacity; or
(v) a congenital anomaly or birth defect; or (B) requiring, based on
reasonable medical judgment, a medical or surgical intervention
to prevent [any of the previously listed outcomes].”286 Cosmetics
manufacturers would have needed to make available to the FDA
all records regarding cosmetic products that are misbranded or
adulterated under the FDCA.287
The Enhancement Act also called for the Secretary of Health
and Human Services, (the Secretary), to promulgate new
regulations establishing “good manufacturing practices for
cosmetics,”288 and products not made in accordance with good
manufacturing practices would have been designated as
“adulterated” under the FDCA.289 In addition, the bill would
have allowed manufacturers to voluntarily recall a cosmetic
product that was likely adulterated where the use of the product
283. Id. § 3(b).
284. Id. The Enhancement Act would also have required the payment of $500
by each registering facility for annual registration fees, beginning in 2013. Id. §
2(d). This fees provision was scheduled to sunset, with no fees authorized after
2017. Id.
285. H.R. 4262 § 4(c), 112th Cong. (2012).
286. Id. § 4(c).
287. Id. § 5(a).
288. Id. § 6(b).
289. See id. §§ 2(b), 6(a).
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would cause serious adverse health consequences or death to
humans, and it would have allowed the FDA to order a
mandatory recall if a voluntary recall is not obtained.290
While a law introduced along the lines of this bill would have
been an improvement over current law, given the inclusion of
FDA authority to issue a recall, and the limited requirements
that manufacturers show product safety before it goes to market,
the Enhancement Act was lacking in its failure to attack the
issue of trade secrets and proprietary information in consumer
cosmetic products.291 Additionally, the efficacy of the somewhat
ambiguous language requiring “good manufacturing practices” is
questionable, given the FDA’s history of deferring to industry in
terms of adopting any new manufacturing rules.292
The Amendments Act, another federal legislative proposal,
introduced by Rep. Leonard Lance (R-N.J.) in 2012,293 also
required the registration of cosmetics manufacturers and of
cosmetic products.294
Only manufacturers performing the final steps of the
manufacturing process would have been required to register, and
the registration would have consisted of the company’s name,

290. Id. § 7(b).
291. The Enhancement Act is silent on the matter of trade secrets or
proprietary information. Furthermore, serious adverse event reports would be
classified as medical files that are not subject to public disclosure. H.R. 4262 §
4(c), 112th Cong. (2012).
292. See, e.g., Schaffer, supra note 66, at 200-01. Schaffer describes the
history of good manufacturing practices for eye makeup as follows:
In 1977, FDA announced that it intended to institute Good
Manufacturing Practices for eye makeup preservatives as a first step
towards Good Manufacturing Practices for all types of cosmetics.
Rather than protesting against such imposition of Good
Manufacturing Practices, the [Cosmetic, Toiletry and Fragrance
Association] merely filed a petition stating what the industry would
prefer to see in Good Manufacturing Practices.
FDA then
incorporated the cosmetics industry’s petition into the Good
Manufacturing Practice guidelines featured in the FDA
‘Investigations Operations Manual.’ Since then, FDA has removed
the guidelines and so ended federal cosmetics Good Manufacturing
Practices altogether.
Id.
293. See H.R. 4395, 112th Cong. (2012).
294. Id. §§ 3-4.
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address, and other contact information.295 The FDA could have
thus suspended a manufacturer’s registration for violations of the
FDCA, where such violation presented a “significant risk of
serious adverse health consequences or death to humans.”296 The
bill called for exceptions to product registration, where
manufacturers had previously filed voluntary cosmetic ingredient
statements that contained what the FDA has determined to be
confidential trade secrets.297 This allowance for the continuation
of the “trade secret formulation” severely weakened the bill.
As under the Enhancement Act, the Amendments Act would
have required the filing of unexpected, adverse event reports with
the FDA within fifteen business days,298 but it did not require the
filing of a report for an adverse event that was listed on the
current labeling.299 The Amendments Act also specifically stated
that adverse effect reports do not “constitute an admission that
the cosmetic involved, caused or contributed to the adverse
event.”300
The Amendments Act explicitly stated that, “a
cosmetic shall be deemed to be safe if it does not present a risk of
significant illness or injury to humans under the conditions of use
recommended or suggested in the labeling.”301
The Amendments Act would also have required the Secretary
to issue rules establishing good manufacturing processes for
cosmetic products.302 In contrast to the Enhancement Act, under
the Amendments Act, cosmetic products made in ways that did
not follow good manufacturing processes would not have been
automatically considered to be adulterated.

295. Id. § 3.
296. Id. Note that, unlike the Enhancement Act, this provision does not
address health consequences or death to animals. H.R. 4262 § 2(c), 112th Cong.
(2012).
297. H.R. 4395 § 4, 112th Cong. (2012). Note that the actual text of the
Amendments Act regarding these exceptions is inaccurate in its cross-references
to existing regulations. It refers to cosmetic ingredient statements filed under
21 C.F.R. § 710, although such statements are authorized under 21 C.F.R. §
720.8(b). Section 710 actually concerns the voluntary registration of cosmetic
product establishments (manufacturers and packers).
298. H.R. 4395 § 5, 112th Cong. (2012).
299. See id.
300. Id.
301. Id. § 12.
302. Id. § 6.
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The Secretary would also have been permitted, or required in
response to a petition, to establish tolerance levels for
nonfunctional constituents in cosmetics.303 In this manner, this
bill introduced the questionable QRA process that governs so
much of toxics regulation.304 A “nonfunctional constituent” in a
cosmetic is defined as “any substance that is an ancillary part of
an ingredient or the manufacturing process, has not been added
as a separate substance, and serves no cosmetic function in the
cosmetic.”305
The law would thus have required that the
tolerance level be set at a level that is “necessary for the
protection of the public health using generally recognized
principles of scientific risk assessment,” and required risk
assessors to consider what is “reasonably achievable through good
manufacturing practices,” and ensure that such tolerance level is
consistent with that established by authoritative scientific or
regulatory organizations.306 As noted elsewhere in this article,
while signaling recognition of potential risk, this proposed
reliance upon the highly subjective QRA process with respect to
cosmetics—many containing EDCs—would be extremely
problematic.307 This is especially true with the bill’s limitation in
setting any tolerance to that which is “reasonably achievable,”
opening the door to a potential weakening of the safety
standard.308
Another extremely significant problem with the Amendments
Act was that findings in a final report by the CIR Expert Panel,
privately organized and funded by the cosmetics industry,309
regarding the safety of a cosmetic product would have been
deemed recommendations to the Secretary, and would have been
accepted unless the Secretary specifically determined
otherwise.310 The bill stated that the CIR Expert Panel could
determine whether a cosmetic ingredient:

303. Id. § 7.
304. See Watnick, supra note 68, at 1316-26.
305. H.R. 4395 § 7, 112th Cong. (2012).
306. H.R. 4395 § 7, 112th Cong. (2012).
307. See supra notes 97-104 and accompanying text.
308. Id.
309. About the Cosmetic Ingredient Review, COSMETIC INGREDIENT REV.,
http://www.cir-safety.org/ about (last visited Feb. 21, 2014).
310. H.R. 4395 § 8, 112th Cong. (2012).
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(1) is safe for use in cosmetic products without the need for
specified conditions of use; (2) is safe for use in cosmetic products
under specified conditions for use; (3) is not safe for use in a
cosmetic product under any conditions of use; [or] (4) requires
more information in order to make a determination whether the
ingredient is safe for use in a cosmetic product under any
conditions or use. . . .311

Thus, the Secretary could ban cosmetic ingredients that fall
under determinations (3) and (4), or (2) if there were
noncompliance with applicable conditions. This reliance on an
industry organization, where the Secretary does not generally
have the resources to “determine otherwise” also weakened this
bill considerably.312
The Amendments Act also permitted—or required, in
response to a petition—the Secretary to evaluate the safety of any
ingredient in a cosmetic product, and establish conditions for the
safe use of such ingredient.313 Again, this presumed that the
Secretary had the resources and political will to identify and then
test suspicious ingredients or products—a specious presumption
at best.
The proposed Amendments Act would also have authorized
the creation of a National Cosmetic Regulatory Databank, which
would have included: cosmetic manufacturing registrations;
cosmetic ingredient statements; adverse event reports; and other
information deemed appropriate.314 The Secretary would also
have been given access to company records to determine whether
a cosmetic product was adulterated and presented a threat of
serious adverse health consequences or death to humans.315 This
access to records was, however, significantly limited by the
condition that the provision “[did] not extend to cosmetic product
formulas,” and other potentially proprietary data.316
Another provision in the Amendments Act would have
prohibited states or localities from establishing laws regarding

311.
312.
313.
314.
315.
316.

Id.
See supra notes 37-40, 64-69 and accompanying text.
H.R. 4395 § 9, 112th Cong. (2012).
See id. § 10.
Id. § 11.
Id.
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cosmetics that differ from the requirements of the FDCA, or from
rules promulgated by the Secretary.317 The Amendments Act did
provide that imported cosmetics would have to have cosmetic
establishment registration numbers and cosmetic ingredient
statement numbers—numbers that are now only voluntarily
provided by importers.318
B. The Safe Cosmetics and Personal Care Products
Act of 2013
The Safe Cosmetics and Personal Care Products Act of 2013
(SCA),319 the strongest of the three recent federal proposals, and
the one that is currently in the House of Representatives that
would amend the FDCA, was first introduced under a slightly
different name in the House of Representatives during 2011.320
The SCA was a revised version of the 2010 Safe Cosmetics Act,
which did not survive committee.321 The SCA provides for the
mandatory registration of cosmetic products manufacturers.322
Registration would include all cosmetic products made, gross
sales from such products, and the source and name of ingredients
received from other entities.323 Under the SCA, the Secretary
would compile a list of all registered establishments and make
such list available to the public.324 Registered establishments
would also need to pay an annual registration fee, as set by the
Secretary, which would vary based on the establishment’s gross

317. Id. § 14.
318. See id. § 15; see Voluntary Cosmetic Registration Program (VCRP), FDA,
http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/Volu
ntaryCosmeticsRegistrationProgramVCRP/#Registering_establishments
(last
visited Feb. 28, 2014).
319. See H.R. 1385, 113th Cong. (2013).
320. See Tobias J. Gillett, Note, Lessons from Nutritional Labeling on the 20th
Anniversary of the NLEA: Applying the History of Food Labeling to the Future of
Household Chemical Labeling, 37 WASH. U. J.L. & POL’Y 267, 294 (2011).
321. Id. at 294 n. 181.
322. H.R. 1385 § 612(a). Microbusinesses, defined as businesses with less
than $2 million in annual sales receipts for cosmetic products, would be exempt
from registration under the SCA. Id. §§ 611(7), 612(a)(1).
323. See id. § 612(b).
324. Id. § 612(d).
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receipts or sales, and would only be imposed on companies with
annual gross receipts or sales in excess of $10 million.325
The SCA would also change the reporting of cosmetic
ingredients. “Ingredient” would be specifically defined to include
the components of a “fragrance, flavor or preservative,”326 thus
eliminating the “trade secret” loophole.327 Additionally, the
ingredient list would be required to incorporate any contaminants
that are present at more than the lower of: (1) “one part-perbillion by weight of product formulation;” or (2) “one percent of
the restriction on the concentration for such contaminant for such
use, as determined [on the list of restricted ingredients].”328 The
SCA would also authorize the Secretary to require ingredients to
be specifically labeled as “nano-scale” if particles are 100
nanometers or smaller in at least one dimension, or require other
scale-specific ingredient information if such ingredients pose
scale-specific hazards.329 Web pages selling cosmetics would
similarly be required to present complete ingredients lists.330
The SCA also calls for the Secretary to establish safety
standards for cosmetics and ingredients that provide a reasonable
certainty of no harm from exposure and protect consumers “from
any known or anticipated adverse health effects . . . .”331
“Reasonable certainty of no harm” is defined as no harm caused
to members of the general public or any vulnerable population332
from aggregate exposure, taking into account low-dose exposures,
additive effects from repeated exposure over time, and cumulative
exposure from all sources including from cosmetic and
environmental sources.333 Safety standards would be intended to
meet either of two tests: (1) likely exposure will not result in

325. Id. § 612(e).
326. Id. § 611(5)(E).
327. Id. § 613(f); see supra notes 183-88 and accompanying text.
328. H.R. 1385 § 613(c), 113th Cong. (2013).
329. Id. § 613(d).
330. Id. § 613(e).
331. Id. § 614(a)(1).
332. “Vulnerable populations” under the SCA would include “pregnant women,
infants, children, the elderly, and highly exposed populations, including workers
employed by hair salons, nail salons, beauty salons, spas, other establishments
that provide cosmetic treatment services for humans, and cosmetic
manufacturing plants.” Id. § 611(13).
333. Id. § 611(9).
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“more than a one-in-a-million risk for any adverse health effect in
any vulnerable population at the lower 95th percentile confidence
interval;” or (2) exposure will produce no adverse health effects
with a margin of safety of at least 1000, and considering
cumulative exposure from all sources.334 The SCA would also
require the Secretary to establish good manufacturing practices
for cosmetics manufacturers.335 The inclusion of this one-in-amillion standard is generally considered to be a negligible risk
standard.336 Moreover, the addition of the vulnerable population
as the benchmark, as well as recognition of the potential longterm effects of consumer cosmetic products, makes the standard
considerably more health protective than other ostensibly healthbased standards.337
Manufacturers would thus be required under the SCA to
provide to the FDA all information regarding safety of their
cosmetics and ingredients.338 This safety data would include
information functions and uses, information on physical,
chemical, and toxicological properties, exposure and rate
information, and the results of all safety tests.339 The FDA would
also be required to establish a publicly available database of all
non-confidential safety information provided.340 The FDA would
use this information, as well as information from other
authoritative sources, to evaluate the safety of cosmetics and
their ingredients, specifically considering the potential harms of
nanomaterials.341
The SCA would also establish lists of prohibited, restricted,
and “safe without limits” ingredients for use in cosmetic products,
in a manner akin to the EU cosmetics regulations.342 To
determine the placement of substances on any of the lists, the
FDA would take into account whether the substance: (1) reacts
334. H.R. 1385 § 614(a)(2)(A)-(B), 113th Cong. (2013).
335. Id. § 614(b)(1).
336. Watnick, supra note 97, at 1337.
337. Our past failure to consider vulnerable populations such as children and
pregnant woman has been the author’s long-time criticism of U.S. toxics
regulatory frameworks. Watnick, supra note 97, at 1320-24.
338. H.R. 1385 § 615(a)(1)(A)-(B), 113th Cong. (2013).
339. Id. § 615(a)(2)(A)-(D).
340. Id. § 615(b)(1).
341. Id. § 615(c)(1)-(2).
342. Id. § 616(a)(1)(A)-(B).
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with other substances; (2) is found in the body; (3) is found in
drinking water or air; (4) is a “known or suspected neurological or
immunological toxicant, respiratory asthmagen, carcinogen,
teratogen, or endocrine disruptor, or [has] other toxicity concerns
(including reproductive or developmental toxicity)”; or (5) is
known to persist in the environment or living tissue.343 Under
the SCA, manufacturers would thus be required to eliminate or
restrict the use of ingredients on the prohibited or restricted lists
within one year of listing.344 A further priority assessment list
would be established for items that cannot be otherwise listed for
lack of information, and for which a safety determination is a
priority.345 If, within five years of placement on the priority
assessment list, there is insufficient information to list the
substance on the prohibited, restricted, or “safe without limits”
lists, such ingredient would be prohibited from use in cosmetic
products.346
Cosmetic products made of only ingredients in the “safe
without limits” use or the restricted list—where such use is in
compliance with the restrictions on the use—would be presumed
to meet safety standards.347 However, manufacturers might be
required to establish a product’s safety if it “contains penetration
enhancers, sensitizers, estrogenic chemicals, or other similar
ingredients,” or contains ingredients that interact to form
harmful byproducts.348 This latter requirement seems aimed at
protecting against interactions in products as seen in the baby
shampoo news headlines.349
The FDA would be mandated under the SCA to establish a
list of: (1) cosmetic ingredients that may contain contaminants;
(2) ingredient combinations that may create contaminants; (3)

343. Id. § 616(a)(2)(A)-(E). The SCA defines “reproductive or developmental
toxicity” as contributing to “biologically adverse effects on the development of
humans or animals, including effects on the female or male reproductive system,
the endocrine system, fertility, pregnancy, pregnancy outcomes, or modifications
in other functions of the body that are dependent on the integrity of the
reproductive system as well [as] normal fetal development. Id. § 611(10).
344. H.R. 1385 § 616(b)(4)(A)-(B), 113th Cong. (2013).
345. Id. § 616(d)(1)(A)-(B).
346. Id. § 616(d)(6)(A).
347. Id. § 617(b)(1)(A)-(C).
348. Id. § 617(b)(2)(A)-(B).
349. See supra notes 3-5 and accompanying text.
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contaminants that may leech from product packaging; or (4) any
other cosmetic contaminant.350 The FDA then would establish
testing procedures for the listed contaminants.351 The FDA
would be required to respond within six months to reasonable
petitions to add items to the prohibited, restricted, or priority
assessment lists, remove items from the “safe without limits” list,
or add items to the list of contaminants.352 In this way, the FDA
would, for the first time, have to promptly respond to consumer
concerns regarding cosmetic formulations.
Also under the SCA, brand owners would be required to
report adverse health effects to the FDA.353 Such reports would
be made accessible to the public, with redactions for personally
identifiable information.354
Another provision of the SCA
specifically provides that any non-confidential information
submitted to the FDA would be made available to the public,
including: (1) the name, identity, and structure of substances,
contaminants, or impurities; (2) information regarding “the
function, exposure, toxicity data, health hazards, and
environmental hazards for a cosmetic;” (3) the function of
ingredients in a cosmetic; and (4) cosmetic fragrance, flavor, and
colorants.355 The concentration of ingredients, however, in a
finished product would be considered confidential business
information, and would not be made available to the public.356
Entities would be permitted to petition for information to remain
confidential by showing that the release would have a serious
negative impact on its commercial interests, although the FDA
could choose to not prevent the disclosure of: (1) the name,
identity, and structure of an ingredient, contaminant, or
impurity; or (2) the health and safety data related to the
ingredient, contaminant, or impurity.357
And finally, any
cosmetic brand owner, manufacturer, packager, retailer, or
distributor with reason to believe that a cosmetic is “adulterated

350.
351.
352.
353.
354.
355.
356.
357.

H.R. 1385 § 618(a)(1)-(4), 113th Cong. (2013).
Id. § 618(c).
Id. § 621(a)(1)-(4).
H.R. 1385 § 622(a), 113th Cong. (2013).
See id. § 622(d)(1)-(2).
Id. § 623(a)(1)-(4).
Id. § 623(b).
Id. § 623(c)(1)-(2).
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or misbranded in a manner that presents a reasonable
probability” of causing severe adverse health effects or death
would have to notify the Secretary.358
Under the SCA, the FDA would thus have the clear authority
to issue a voluntary recall and give notice of this recall if it
believed a cosmetic was adulterated, misbranded, or otherwise in
violation of the FDCA (as amended).359 And, if this voluntary
recall were not observed, to order that the product sales cease,
and to ultimately order a mandatory recall.360
The SCA would also mandate that the FDA establish
alternative testing procedures to minimize the testing of
ingredients and cosmetics on animals.361 Under the SCA, the
FDA would also conduct annual tests of random cosmetic
samples, testing for “negative reactions, pathogen hazards,
contaminants, leaching of packaging additives, mislabeling, or
other relevant issues of concern . . . .”362
The SCA would likewise significantly broaden the definitions
of adulterated and misbranded cosmetics to include cosmetics
that: (1) do not meet established safety standards; (2) contain
ingredients on the prohibited list or the restricted list, in excess of
the limits established by such list; (3) do not properly list or
package their products; or (4) do not pay fees and report severe
adverse effects.363
Overall, the SCA would significantly strengthen U.S.
cosmetics law by: (1) requiring the registration of cosmetic
manufacturers; (2) creating a prohibited and “safe without limits”
list of ingredients; (3) doing away with the trade secret and
proprietary
information
loopholes;
and
(4)
requiring
manufacturers to share safety testing and provide adverse health
358. Id. § 620(a)(1).
359. H.R. 1385 § 620(b), 113th Cong. (2013). If there was reason to believe
that a cosmetic might cause serious adverse health effects or death, is
misbranded, or is manufactured by an unregistered facility, the FDA could issue
an order stopping distribution of the product or an order to mandatorily recall
the cosmetic under the SCA. The FDA might also provide information regarding
any recall to the general public and to state and local officials. Id. § 620(c)–(d),
(f).
360. See H.R. 1385 § 620(c), 113th Cong. (2013).
361. See id. § 624(a)(1).
362. Id. § 625.
363. See id. §§ 601, 602.
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effects information. Furthermore, the addition of clear FDA
recall authority under the bill would be a significant and quite
telling step forward in our effort to regulate U.S. cosmetics to
protect human health and the environment. Given the failure of
earlier versions of this bill to survive committee, the political
feasibility of such a measure seems questionable absent a
monumental shift in public awareness and pressure.364
VI. CONCLUSION
Current U.S. cosmetics law and regulations contain
abundant loopholes and weaknesses, such that they do not
adequately protect human health.
The current regulatory
framework does not call for a consideration of the special
susceptibility of children, pregnant or breastfeeding women, other
vulnerable populations, the potential for danger from EDCs, or
the potential for long-term or synergistic harm from synthetic
chemicals. It also provides no meaningful recall process for the
FDA in the cosmetics arena.
A new regulatory structure should give the FDA recall power,
and require pre-approval of cosmetic formulations and
ingredients based on up-to-date safety data before a product goes
to market, as has been required in other jurisdictions. If we are
to become more health protective in our regulation of consumer
products, the U.S. regulatory paradigm, for cosmetics in
particular and for all consumer products, must shift to a more
precautionary approach. Models for more health protective
legislation are found in many jurisdictions in the developed
world, including Europe, Canada, and Japan, and at home, in
California. Proposed U.S. legislation to strengthen existing law
would offer improvements within the existing paradigm, but at
least two of the most recent federal proposals do not go nearly far
enough to make human health a priority, and the third proposal,
the SCA, has not been politically feasible when introduced in
varying forms in prior Congressional sessions.
Consumer
awareness and resulting public pressure would go a long way

364. See supra notes 5, 159 and accompanying text (noting that planned and
existing corporate changes by Johnson & Johnson and by Walmart were largely
attributed to public pressure).
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toward strengthening U.S. cosmetic products regulation to make
it more health protective.
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